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Upper limb ischaemia – a twelve year experience 
 
Authors: Dr JM du Toit, Dr NG Naidoo (Department of Vascular Surgery, Groote Schuur Hospital) 
 
Introduction: Upper limb ischaemia (ULI) is a relatively uncommon, but well recognized vascular entity. The 
sequalae of impaired function or amputation of an arm can be devastating to the individual with loss of 
independence and / or livelihood. There remains much to be learned that can only be established through good 
quality studies. This project was aimed at developing a comprehensive, but broad overview of ULI, specific to 
the population we serve. 
 
Aims: The objective was to review the Vascular Surgery Unit’s experience with ULI, with particular emphasis 
on defining the pattern and distribution of disease and pathological profile, describing key demographic and 
clinical features and reporting on conventional clinical outcomes. Areas of interest, with the potential for further 
research, were identified.  
 
Methods: Retrospective descriptive study. All patients that underwent a surgical intervention for ULI between 
January 2000 and December 2011, were included in the audit. Approval from the Department of Surgery 
Research Committee and Human Research Ethics Committee was obtained prior to accessing data (Appendix 1 
& 2). A research folder was compiled for each patient. On completion of the data collection process, the 
findings were analyzed and compared to current literature on this topic.  
 
Results: Sixty-four patients with ULI were managed surgically during the 12 year study period. A male: 
female ratio of 0.60 (as opposed to 0.96 from 2011 Census figures), was reported. The thrombo-embolic 
subgroup of patients (n=30), were notably younger than expected (mean age of 55 years) compared to the 
UEAOD subgroup (n=12, mean age of 57 years). Approximately 48% were of mixed ethnicity, correlating well 
with 2011 Census figures.  Referrals were predominately received from Secondary Hospitals (84%) situated 
within the Cape Metropole. 55% Presented with acute ULI, of which 40% were classified as Rutherford grade 
IIa and 17% diagnosed with established compartment syndrome. The majority of chronic ULI patients, 
presented with signs of tissue necrosis (48%). Other indications for intervention included upper extremity 
claudication symptoms (31%), rest pain (14%) as well as neuro-vascular symptoms (7%). A disproportionately 
high prevalence of cigarette smoking (83%, with an average of 31 pack years) was identified in the UEAOD 
subgroup. 27% Of patients were not receiving adequate pharmacological therapies aimed at addressing pre-
existing risk factors, as proposed by the TASC II document. Thrombo-embolism was the single largest 
aetiological factor identified (47%), with the majority of occlusions (57%) occurring at the level of the brachial 
artery. A left-sided predominance with a ratio of 2:1, was noted. Approximately 47% of patients with UEAOD, 
were younger than 55 years. A clear proximal pattern of disease was observed (66% of lesions within the 
subclavian artery). Eighty-nine procedures were performed in 64 patients (78 open, 5 exclusively endovascular 
with a combined open / endovascular approach implemented in 6 patients). The 30-day mortality rate was 7.8%. 
Systemic complications were observed in 13% with 23% sustaining some form of procedural complication. 
Twenty amputations were performed in 64 patients, of which 6 were major amputations. The 30-day amputation 
rate after an attempt at revascularization, was 12.5%. Adherence to follow-up was poor (51% at 6 months), 
limiting interpretation of follow-up data.       
 
Conclusion: Although few firm conclusions could be drawn, this review has expanded our overall perspective 
of ULI, specific to the population we serve. It is anticipated that the publication of our institutional data will 
create a clinical awareness and facilitate future research projects in this field. A collaborative research effort 
between South African vascular units will facilitate comparison of different institutional experiences and enable 
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Upper limb ischaemia is a relatively uncommon, but well recognized vascular entity 
caused by a wide range of aetiological factors. However, the sequalae of impaired function 
or amputation of an arm can be devastating to the individual with loss of independence 
and / or livelihood. There remains much to be learned that can only be established through 
good quality studies. 
 
Due to the relative infrequency of this condition, few clinicians are familiar with the 
different aspects of diagnosis, investigation and treatment. The occupational ramifications 
and impact on quality of life in those affected can be substantial. A thorough 
understanding of this condition is essential if significant improvement in surgical outcome 
and limb functionality is to be made. These considerations were the inspiration behind the 
current study, with the purpose of improving colleagues’ (as well as the author’s) insight 
into the disease by defining the pattern and distribution of disease and pathological 
profile, describing key demographic and clinical features and reporting on conventional 
clinical outcomes. 
 
The project was aimed at developing a comprehensive, but broad overview of upper limb 
ischaemia, specific to the population we serve. Areas of interest, with the potential for 







1) GENERAL CONSIDERATIONS AND OVERVIEW 
A computerized search of the National Library of Medicine and the National Institutes of 
Health MEDLINE database was undertaken using the Entrez PubMed (www.pubmed.gov) 
interface, followed by a secondary manual search of the article reference lists. The 
primary search strategy was developed to retrieve English language articles focusing on 
upper limb ischaemia published between 2000 and 2013; letters to the editor, editorials 
and other items of general commentary were excluded from the search. Studies reporting 
on upper limb ischaemia related to primary Raynaud’s phenomenon and trauma were 
excluded, as they were beyond the scope of this review. 
 
The above literature search resulted in a heterogeneous group of articles related to upper 
limb ischaemia. No randomized trials or prospective studies were identified. Clinical data 
were limited to case reviews derived from a range of sources, including district general 
hospitals, regional centres as well as specialist vascular units. Most of these publications 
reported on a single clinical (either acute or chronic) or aetiological (either traumatic or 
non-traumatic) aspect of upper limb ischaemia. Understandably, series that combine acute 
and chronic ischaemia are rare.[1,5-7] Often, by attempting to discuss two distinctly different 
disease processes concurrently, important individual characteristics may be obscured.  
 
 
Popular research themes subsumed within the published surgical series, included 
comparisons of different management pathways (particularly operative versus non-
operative management of acute upper limb ischaemia), clinical outcome of different 
interventional modalities (specifically percutaneous versus open surgical procedures) as 
well as reviews of specific aetiological entities. The applicable articles were reviewed, 
including relevant references from the perused material.  
 
Due to the wide spectrum of underlying aetiologies and clinical presentations, it is of 
utmost importance that interesting findings from the literature are presented in a logical 
and structured manner. This may be accomplished by implementing a rigid clinical or 
aetiological framework. Instead, the relevant findings will be presented under the 
following headings, in order to accommodate for the complexities and heterogeneity 
associated with this condition. 
 Incidence and demographics 
 Risk factors  
 Aetio-pathology 
 Anatomical basis of disease 
 Clinical presentation and related management pathways 
 Outcome 
 
2) INCIDENCE AND DEMOGRAPHICS 
Patients managed non-surgically are often excluded from these series. This prevailing 
limitation adds to the difficulty in determining the true incidence of upper limb ischaemia 
as well as establishing an accurate ratio of acute to chronic presentations. Most authors 
 
agree that ischaemic conditions of the lower extremity are much more common than those 
of the upper extremity.[1-3] Upper limb revascularization procedures comprise 
approximately 4% of all vascular procedures performed and constitute around 15-18% of 
all interventions performed for critical limb ischaemia.[4,5]  
 
There seem to be unique demographic differences between upper and lower extremity 
bypass populations.[8-10] Hughes et al[9] reviewed their single centre experience and noted 
that patients presenting for upper extremity revascularization do so at a relatively early age 
(average age 57 years) with a slight female preponderance of 55%, a fairly consistent 
finding throughout the literature.[2,5] In contrast, a contemporary cohort of lower extremity 
bypass patients from the same institution, had a mean age of 67 years with a primarily 
male preponderance of 62%.  
 
The bypass population is not the only subgroup of patients reflecting subtle 
epidemiological differences between upper and lower limb cohorts. When considering 
acute limb ischaemia (defined as a sudden decrease in limb perfusion posing a potential 
threat to limb viability, presenting within 2 weeks of an acute event)[11], it is clear that this 
condition affect the lower limbs much more commonly (reported incidence of 1.3 cases 
per 100 000 per year),[4] than the upper limbs. Acute upper limb ischaemia (AULI) occurs 
in a slightly different patient population than acute lower limb ischemia,[12]  partially 
explained by an unequal distribution of atherosclerotic occlusive disease, mostly affecting 
the lower limbs. AULI is also found in a more heterogeneous group of patients, presenting 
as a clinical manifestation of conditions such as inflammatory vasculitides, iatrogenic 
disorders (drug related, arterial catheterization and radiation fibrosis), arterial thoracic 
outlet syndrome and atherosclerotic occlusive disease. 
Embolic disease affect the upper limbs more frequently.[13] Emboli are the most frequent 
cause of upper limb ischaemia. Of all arterial embolizations, between 10 and 20% involve 
the upper limbs. However, a number of recent studies have estimated the frequency of 
peripheral arterial embolic occlusions, to be on the decrease.[14,15] Multiple factors are at 
play, continuously influencing the incidence of embolic phenomena. Even though the 
frequency of systemic emboli due to ischaemic heart disease is on the increase, the 
absolute number of embolic events is believed to have declined, mostly due to a decrease 
in the number of rheumatic heart disease patients as well as widespread use of long-term 
anticoagulation in the management of rheumatic heart disease and atrial fibrillation.[16-18]   
As previously stated, series that combine both acute and chronic upper limb ischaemia are 
rare.[1,5,18,19] The largest of these included 172 patients undergoing revascularization 
procedures for upper limb ischaemia over a 20 year period.[1] The age of presentation 
depended heavily on the underlying aetiology at hand. The mean age of presentation of 
patients with thrombo-embolic disease was appreciably older (72.4 years) than those 
presenting with upper extremity atherosclerotic occlusive disease (62.5 years). This may 
partly explain the higher incidence of severe comorbid disease observed in patients 
presenting with thrombo-embolism, as opposed to atherosclerotic occlusive disease. 
3) PREDISPOSING CONDITIONS
When considering the prevalence and contribution of predisposing conditions, it is 
important to interpret them in terms of the underlying aetio-pathology at hand. For 
instance, the presence of atrial fibrillation is a strong predisposing factor for cardio-
embolic events, but not the development of atherosclerotic occlusive disease. This section 
will focus on traditional risk factors for atherosclerotic occlusive disease and their 
applicability to UEAOD. 
3.1) Risk factors for atherosclerosis and the development of upper extremity 
atherosclerotic occlusive disease (UEAOD) 
The best quality evidence regarding this topic takes the form of multiple consensus 
documents (including the TASC II document, American Heart Association and American 
College of Cardiology guidelines). However, it is important to note that most data 
pertaining to risk factors for non-coronary atherosclerotic arterial disease, have been 
extrapolated from studies primarily focusing on coronary artery disease (CAD), such as 
the Framingham Heart Study, Atherosclerosis Risk in Communities Study (ARIC),[19] 
Honolulu Heart Study,[20] and the Strong Heart Study.[21] With rare exception, the 
evidence from these studies suggests that risk factors for non-coronary atherosclerotic 
arterial disease are generally similar and independent of the end organ affected.  
Despite the superfluous reports on the effects of atherosclerotic risk factors in lower 
extremity arterial disease, none such studies specific to UEAOD could be identified. The 
prospect of generating good quality population based data in future (specific to the 
UEAOD cohort), are unlikely, particularly in light of a recent (2008) document produced 
by the American Heart Association.[22] In an attempt to clarify nomenclature pertaining to 
non-coronary atherosclerotic arterial disease, they suggested that the term PAD should 
incorporate both lower and upper extremity atherosclerotic arterial disease.  
Recently published surgical series on UEAOD (Table 1), have reported the following 
prevalence of traditional atherosclerotic risk factors. 
Table 1: Studies evaluating prevalence of risk factors in UEAOD  
Study  n  Smoking(%) HPT(%)  DM (%) 
Hughes et al, 2013 [9]   55 35 Not reported 29 
Spinelli et al, 2009 [23] 23 43 26 48 
Hughes et al, 2007 [9]  20 Not reported 45 40 
Hughes et al[9] noted a statistically significant difference in the prevalence of diabetes 
mellitus in upper extremity bypass patients (40%) compared to the lower extremity bypass 
population (83%). Differences in the prevalence of hypertension, coronary artery disease, 
congestive cardiac failure and tobacco use were not statistically significant.[9,23] 
The criteria used to support a risk factor for UEAOD (as opposed to a strong association), 
require a prospective, controlled study showing that modifying the factor alters the 
development or course of the disease. Until such studies are produced, the best evidence 
on the impact of traditional risk factors on the development and progression of UEAOD, 
takes the form of extrapolated data from non-coronary atherosclerotic arterial disease 
 
studies. The rest of this section will attempt to shortly review these traditional risk factors, 
including proposed therapeutic targets in the presence of disease. 
 
Figure 1: Approximate odds ratio range for atherosclerotic risk factors as depicted by the 
TASC II document [24] 
 
 
3.1.1) Tobacco products 
The relationship between smoking and PAD has been recognized since 1911, when Erb 
reported that intermittent lower limb claudication was three times more common among 
smokers than non-smokers.[24] Tobacco use is particularly prevalent in patients with 
UEAOD and seems to have a stronger causative association than the aforementioned risk 
factors. It has been suggested that the association between smoking and PAD may be 
stronger than that of smoking and coronary artery disease (CAD). The number of pack 
years is associated with disease severity, an increased risk of amputation, peripheral graft 
occlusion and mortality. Given these associations, smoking cessation has been the 
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cornerstone of PAD management. However, due to low smoking cessation rates achieved 
with medical therapy, modification of this risk factor may be particularly challenging.  
 
Multiple randomized controlled trials have supported the use of an antidepressant, 
bupropion, in establishing improved smoking cessation rates. Jorenby et al (Figure 2) 
have shown that bupropion, when combined with nicotine replacement therapy, is more 
effective than either therapy alone.[25] This should be combined with non-pharmacological 
strategies, including physician advice at every patient visit and behavioural modification 
therapy, in order to achieve the best cessation rates.  
 
Recently, substance abuse has been implicated in the processes of accelerated and 
precocious atherosclerosis as well as Thromboangiitis obliterans. Some of the finer 
pathological implications of tobacco use and other substances will be discussed in the 
section on aetio-pathology.  
 
Figure 2: Comparative abstinence rates for bupropion, nicotine replacement therapy or 




































3.1.2) Diabetes mellitus 
Many studies have shown an association between diabetes mellitus and the development 
of PAD. In patients with diabetes, for every 1% increase in haemoglobin A1c, there is a 
corresponding 26% increased risk of developing PAD.[26]  Over the last decade, mounting 
evidence has suggested that insulin resistance plays a key role in the clustering of cardio-
metabolic risk factors (also referred to as Metabolic syndrome or Syndrome X) which 




In the Framingham study, a fasting total cholesterol > 7 mmol/L was associated with a 
doubling in the incidence of intermittent lower limb claudication. However, the ratio of 
total to high-density lipoprotein (HDL) cholesterol was the best predictor of risk for PAD. 
Although some studies have shown total cholesterol to be a powerful independent risk 
factor for PAD, others have failed to confirm this association.  
 
Good quality evidence supporting the use of statins to lower LDL cholesterol in PAD 
patients, were obtained from the Heart Protection Study. [27] Over 20 500 subjects at high 
risk for cardiovascular events (including 6748 patients with PAD), were enrolled. Patients 
were randomized to simvastatin 40 mg, antioxidant vitamins, a combination of treatments 
or placebo, with a 5-year follow up period. Simvastatin 40 mg was associated with a 12% 
reduction in total mortality, 17% reduction in vascular mortality, 24% reduction in CAD 
events, 27% reduction in cerebrovascular events and a 16% reduction in non-coronary 
revascularizations. Similar results were obtained in the PAD subgroup, whether they had 
 
evidence of coronary artery disease at baseline or not. Importantly, there was no threshold 
cholesterol value below which statin therapy was not associated with benefit. A limitation 
of this study was that the evidence in PAD was derived from a subgroup analysis of 
symptomatic PAD patients. 
 
A more recent meta-analysis of 14 randomized trials pertaining to statin therapy, 
concluded that a 1 mmol/L reduction in the level of LDL cholesterol, was associated with 
a 20% decrease in the risk of major cardiovascular events.[28] This benefit was also not 
dependent on the initial lipid levels. 
 
3.1.4) Hypertension 
Hypertension is associated with all forms of cardiovascular disease, including a two- to 
three- fold increased risk of developing PAD. However, the relative risk for developing 
PAD is less than for diabetes or smoking. Current hypertension guidelines support the 
aggressive treatment of blood pressure in patients with atherosclerotic occlusive disease, 
targeting a blood pressure of 140/90 mmHg. In the subgroup of patients with diabetes or 
renal insufficiency, a blood pressure of 130/80 mmHg should be targeted.[29,31] 
 
3.1.5) Hyperhomocysteinemia 
The prevalence of hyperhomocysteinaemia in the PAD population, is significantly higher 
than in the general population (prevalence of 1%). It is reported that 
hyperhomocysteinaemia is detected in about 30% of young patients (aged 55 or below) 
with PAD. The suggestion that this condition may be an independent risk factor for 
atherosclerosis, has now been substantiated by several studies. As with cigarette smoking, 
 
it may be a stronger risk factor for PAD than for CAD. While B-vitamin and / or folate 
supplementation can lower homocysteine levels, this does not reduce the incidence of 
cardiovascular events. Two studies investigating this supplementation regime in patients 
with CAD, demonstrated no benefit and even a suggestion of harm.[31,32] 
 
3.1.6) Chronic renal insufficiency 
A strong association of renal insufficiency with PAD has been reported, with some recent 
evidence suggesting it may be causal. The HERS study (Heart and Estrogen / Progestin 
Replacement Study) reported an independent association of renal insufficiency with future 
PAD development in postmenopausal women.[33]   
 
4) AETIO-PATHOLOGY 
Multiple approaches to the classification of upper limb ischaemic conditions have been 
described. None are more clinically relevant than categorizing patients into acute or 
chronic ischaemia, according to the duration of their symptoms. This approach assists the 
clinician in deliberating the most appropriate management pathway, while honing in on 
the most common underlying aetiologies. Although essential in the clinical setting, this 
classification does not lend itself to an in depth discussion of different aetiological factors. 
A more appropriate classification system for discussion purposes is illustrated below 
(Table 2). Causes of ULI are divided into two broad categories, namely Upper Extremity 
Occlusive Disease (UEOD) and Thrombo-Embolic Disease (TED). The limited nature of 
this dissertation does not allow for in depth discussion of each and every aetio-
pathological factor. Therefore, the most common and interesting aetio-pathologies in each 
category, will be discussed in more detail. 
Table 2: A proposed aetio-pathological classification of upper limb ischaemia 
UEOD    TED              
Atherosclerosis (UEAOD) Cardiac source 
Thromboangiitis obliterans 
Vasculitides 
     Small vessels: 
    Connective tissue disorders 
             Systemic sclerosis (Scleroderma) 
Mixed connective tissue disease 
Systemic Lupus Erythematosus 
Polymyositis / Dermatomyositis 
Sjögren’s syndrome 
Rheumatoid arthritis 
     Large vessels: 
Giant cell arteritis 
Takayasu’s disease 
          Radiation arteritis 
Secondary vasospastic disorders 
          Drug-induced 
Iatrogenic 
Recreational 




        Non-valvular: 
             Atrial fibrillation 
             Ischaemic cardiomyopathy 
             Myocardial infarction 
             Ventricular aneurysm 
             Atrial myxoma 
             Paradoxical emboli via PFO 
        Valvular:    
             Rheumatic heart disease 
             Bacterial endocarditis 
             Sequelae of cardiac valve replacement 
   Extra-cardiac source 
        Aortic: 
             Ascending aortic aneurysm 
Non-specific / atypical 
             Complicated atheromatous plaque 
             Pseudo-aneurysm  
Post-traumatic / iatrogenic 
             Aortic dissection 
             Congenital anomaly  
Aberrant right subclavian artery 
Kommerrell’s diverticulum 
        Peripheral: 
             Subclavian aneurysm 
Atherosclerotic / atypical 
             Pseudo-aneurysm 
Post-traumatic / iatrogenic 
             Entrapment syndromes 
             Arterial thoracic outlet syndrome 
Quadrilateral space syndrome 
Brachial artery entrapment  
             Arterio-venous fistula / graft 
             Occupational 
Hypothenar Hammer Syndrome 
 
 
4.1) Upper extremity occlusive disease (UEOD) 
4.1.1) Upper extremity atherosclerotic occlusive disease (UEAOD) 
Most series identify embolic disease, trauma and Thromboangiitis obliterans as the most 
common causes of upper limb ischaemia, followed by UEAOD.[1,9,10]  However, Spinelli 
et al[23] identified atherosclerosis as the most common aetiology (74%) in their upper 
extremity bypass population. This disproportionately high number might be explained by 
the unusually high number of patients with dialysis-dependant renal failure (39%) in their 
study group. 
 
Atherosclerosis may have a variable effect on different arterial segments, both with 
regards to the morphological pattern of disease (ostial, mono- or multi-segmental) as well 
as the degree to which the segment is affected. Despite this variability, it should still be 
regarded as a diffuse disease process affecting multiple vascular beds. Unfortunately, no 
substantial reports (outside of case reports), could be identified to elucidate and help 
differentiate the morphological pattern in UEAOD from other anatomical segments prone 
to the development of atherosclerotic arterial disease.  
 
Atherosclerosis of the upper extremity may manifest in a number of ways. Atheroma 
formation may progress to occlusion or stenosis of the affected segment. These lesions 
develop slowly. Often, several decades will pass before a critical narrowing is evident and 
arterial flow is impaired. This slow progression, as well as the rather robust 




Atheromatous plaque may ulcerate or rupture, resulting in embolization with distal small 
vessel occlusion, eventually propagating to form extensive arterial occlusion. Thrombosis 
occurs less commonly. An initial small mural thrombus may evolve to form a major, near-
occlusive or occlusive thrombus. Ultimately, lesions progress to form organized, fibrotic 
thrombus. 
 
UEAOD predominantly affect the proximal vasculature, including the aortic arch, 
brachiocephalic artery (BCA), subclavian arteries (SCA), axillary and brachial arteries. 
The most extreme example of this process is aortic arch syndrome, where all branches of 
the aortic arch are occluded. Usually, only isolated branches occlude or become stenosed, 
also referred to as partial aortic arch syndrome. Anecdotal evidence suggests that UEAOD 
frequently involve a single segment of the arterial tree, compared to the predominantly 
multi-segmental disease encountered in symptomatic lower extremity atherosclerotic 
occlusive disease.  
 
Less frequently, other more distal segments are affected. These include arteries of the 
forearm and hand. Obliterative disease of these segments are usually caused by distal 
embolization from a proximal atheromatous source. The symptomatology may become 
more severe with coexisting downstream lesions or pre-existing anastomoses.  
 
4.1.2) Thromboangiitis obliterans (TAO) 
Thromboangiitis obliterans (also known as Buerger’s disease) is a segmental, occlusive, 
inflammatory condition of small and medium sized arteries and veins, characterized by 
 
thrombosis and recanalization of the affected vessels.[34,35] It is a non-atherosclerotic 
inflammatory disease of unknown aetiology, usually affecting young men who are heavy 
smokers.[36] It differs from other vasculitides in that the serological markers of 
inflammation and autoantibody formation, are either absent or normal. Pathologically, it 
differs from other forms of vasculitis in that the vessel wall architecture is relatively well 
spared and fibrinoid necrosis is absent. Progressive organization of a highly inflammatory 
thrombus in the vessel lumen, is a consistent finding.[37]  
 
The association between tobacco use and the development of TAO, is incontestable. Use 
or exposure to tobacco plays a central role in the initiation and progression of the disease. 
It remains debatable whether cannabis exposure is really implicated in the 
pathophysiology of distal arteritis in young adults. A recent comprehensive review of the 
literature[38] collected 70 published cases of the so-called cannabis arteritis. In this review, 
97% of cannabis users also smoked tobacco, as cannabis is always consumed mixed with 
tobacco in Europe. Confounding factors like these add to the difficulty in assessing the 
effect of cannabis on the initiation and progression of TAO. In a recent retrospective 
review of 38 consecutive patients with TAO,[39] investigators found that cannabis users 
were significantly younger at onset of arterial disease despite a similar tobacco exposure. 
This greater precocity might suggest an accelerating effect of cannabis on TAO 
pathophysiology. However, a more addictive personality or earlier initiation of tobacco 
use in cannabis consumers, may have affected this observation. Also, in the absence of 
toxicological tests, quantification of cannabis exposure cannot be objectively assessed, 
due to the variability of cannabis concentrations and methods of consumption. 
 
Upper extremity involvement is classic, especially if it presents with Raynaud’s 
phenomenon of recent onset in a young man. Although TAO most commonly affect the 
extremities, case reports implicating this disease process in other vascular beds (including 
cerebral, coronary, intestinal arteries, aorta as well as multi-organ involvement), have been 
published. [40-43]  
A marked decrease in the frequency of the HLA-B12 antigen in patients with TAO (2.2% 
vs. 28% in controls), was previously reported.[44]  Similar to other autoimmune diseases, 
TAO may have a genetic predisposition without the presence of a direct causative gene 
mutation. Most investigators agree that TAO is an immune-mediated endarteritis. Recent 
immunocytochemical studies have demonstrated a linear deposition of immunoglobulins 
and complement factors along the elastic lamina.[45] The inciting antigen has not been 
discovered. The role of hyperhomocysteinaemia in the pathogenesis of TAO is 
controversial.[46] An association between thrombophilic conditions such as 
antiphospholipid syndrome and TAO, has also been suggested.[47]  
4.1.3) Small vessel vasculitides and secondary vasospastic disorders 
A host of inflammatory and vasospastic disorders can result in digital ischaemia. Current 
nomenclature, when describing the clinical manifestation of these disorders, includes the 
terms phenomenon, syndrome and disease. The inconsistency with which terms are used 
to describe these conditions, have led to considerable confusion.  
In Europe, Raynaud’s phenomenon (RP) is used as a blanket term describing all forms of 
cold-related vasospasm, with the term Raynaud’s syndrome (RS) being reserved for RP 
associated with another (secondary) disease process. Raynaud’s disease (RD) describes 
the clinical scenario where RP occurs in isolation. American and Australasian researchers 
use the terms syndrome and phenomenon interchangeably, but differentiate primary from 
secondary RP. The American nomenclature, as described above, has been adopted and 
applied to the current text. 
In the Framingham Offspring Study,  the prevalence of RP was 9.6% in women and 5.8% 
in men.[48]  A familial predisposition have been described, especially if the onset of RP 
was under the age of 30 years.[49]  Primary RP has been described in monozygotic twins, 
but the concordance rate is not currently known.[50]   
Vasospasm is the key feature of RP. Maurice Raynaud originally described this 
phenomenon as “episodic digital ischaemia induced by cold and emotion.”[51] The 
classical manifestation of pallor, preceding cyanosis and rubor, reflects the initial 
vasospasm followed by deoxygenation of static blood and reactive hyperaemia. However, 
the full triphasic colour change is not essential for diagnosis.  
The precise mechanism causing RP is poorly understood, but believed to be due to 
multiple, interdependent factors that interact closely to produce symptoms. These include 
neurogenic, inflammatory, immunological and genetic factors as well as interactions of 
blood constituents with the vessel wall. 
In approximately half of patients with RP, a significant underlying systemic cause can be 
identified. Half of these cases are caused by a connective tissue disorders, most 
 
commonly systemic sclerosis or mixed connective tissue disease. Other conditions 
associated with secondary RP, are listed in Table 3.  
 
Secondary, compared to primary RP, often present with a more severe degree of ischaemia 
due to the presence of established occlusive disease. Residual symptoms on long term 
follow-up as well as mortality, is higher in the patient group with systemic disease, 
compared to local disease associations.   
Table 3: Conditions associated with secondary Raynaud’s phenomenon. 
Category and condition 
 
Incidence of RP 
 
Connective tissue disorders 
     Systemic sclerosis (Scleroderma) 
     Mixed connective tissue disease 
     Systemic Lupus Erythematosus 
     Polymyositis / Dermatomyositis 
     Sjögren’s syndrome 
     Rheumatoid arthritis 










     Distal UEAOD 
     Thromboangiitis obliterans 
     Micro-emboli (Cardiogenic / Arterio-arterial) 




     Hypothenar Hammer Syndrome (HHS) 
     Vinyl chloride disease 
     Ammunition workers 




     β-blockers 
           
 
Miscellaneous 
     Hypothyroidism 
     Cryoglobinaemia 










Interesting occupation-related causes of secondary RP include Hypothenar hammer 
syndrome (will be discussed in the section on thrombo-embolic disease), cold exposure, 
vinyl chloride disease (affecting approximately 3% of exposed workers) and ammunition 
workers (only manifests once the vasodilatory effects of nitrates are removed, i.e. at home 




4.2) Thrombo-embolic disease (TED) of the upper extremity 
At this point, the reader is invited to review Table 2 once more (below), as this will be 
used as a framework to guide discussion on the aetio-pathological aspects of TED. 
 
Table 2: A proposed aetio-pathological classification of upper limb ischaemia 
 






   Cardiac source 
Thromboangiitis obliterans  
Vasculitides 
 
     Small vessels: 
          Connective tissue disorders 
               Systemic sclerosis (Scleroderma) 
               Mixed connective tissue disease 
               Systemic Lupus Erythematosus 
               Polymyositis / Dermatomyositis 
               Sjögren’s syndrome 
               Rheumatoid arthritis 
 
     Large vessels: 
               Giant cell arteritis 
               Takayasu’s disease 
               Radiation arteritis 
           
Secondary vasospastic disorders 
 
          Drug-induced 
               Iatrogenic 
               Recreational 
          Occupational 
               Ammunition workers 






        Non-valvular: 
             Atrial fibrillation 
             Ischaemic cardiomyopathy 
             Myocardial infarction 
             Ventricular aneurysm 
             Atrial myxoma 
             Paradoxical emboli via PFO 
 
        Valvular:     
             Rheumatic heart disease 
             Bacterial endocarditis 
             Sequelae of cardiac valve replacement 
 
   Extra-cardiac source 
 
        Aortic: 
             Ascending aortic aneurysm 
                  Non-specific / atypical 
             Complicated atheromatous plaque 
             Pseudo-aneurysm  
                  Post-traumatic / iatrogenic 
             Aortic dissection 
             Congenital anomaly  
                  Aberrant right subclavian artery 
                  Kommerrell’s diverticulum 
                    
        Peripheral: 
             Subclavian aneurysm 
                  Atherosclerotic / atypical 
             Pseudo-aneurysm 
                  Post-traumatic / iatrogenic 
             Entrapment syndromes 
                  Arterial thoracic outlet syndrome  
                  Quadrilateral space syndrome 
                  Brachial artery entrapment 
             Arterio-venous fistula / graft 
             Occupational 
                  Hypothenar Hammer Syndrome 
                           
 
The most common causes of ALI include arterial embolism, thrombosis and trauma. 





4.2.1) Embolic disease: General remarks 
Emboli may arise from several possible origins. Traditionally, embolic sources have been 
classified as either cardiac or extra-cardiac in origin. Consistently, it has been reported that 
the heart is the most frequent source of emboli followed by the proximal aorta and supra-
aortic trunk.[12,52-53] Approximately two-thirds of emboli involving the upper extremities, 
originate from the heart, with 9–12% classified as cryptogenic. 
 
The origin of the embolus affect the size and consequently the level at which it occludes 
the affected vessel. Emboli originating from the heart are usually larger in size and tend to 
lodge more proximally, often at the bifurcation of the brachial artery. Arterial emboli 
travel more distally, however exceptions to the rule do exist. Haimovici,[13]  reported the 
subclavian artery to be the site of occlusion in 11.7%, the axillary artery in 23%, the 
brachial artery in 61%, the radial artery in 23% and the ulnar artery in 1.6% of patients 
with AULI. Comparison between studies is difficult due to different methods used to 
establish the site of occlusion (clinical, operative and angiographic findings). Despite this 
confounding factor, multiple reports have confirmed the brachial artery to be the most 
commonly occluded artery in the upper limb.[1,2,54,55]  
 
Most authors describe a higher incidence of embolism affecting the right arm compared to 
the left. This phenomenon can probably be explained by the larger diameter of the 
brachiocephalic artery compared to the left subclavian artery as well as the favourable 
angle that exists between the aorta and the brachiocephalic artery.[4] 
 
 
The natural clinical course of a peripheral arterial embolus depends upon the location of 
the occlusion, the completeness of luminal obliteration, the extent of secondary 
thrombosis and the degree of spontaneous restoration of the collateral circulation. 
Occlusion of the subclavian artery is usually well tolerated and compensated for by 
collateral blood supply. The axillary artery, too, has a rich collateral blood supply from the 
more proximal subclavian branches (Figure 3). Combined subclavian and axillary 





Figure 3: Schematic representation of collateral circulation pathways around the right 
shoulder joint in the setting of SCA occlusion 
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Occlusion of the brachial artery has different effects, depending on the site of occlusion, 
presence of collateral branches as well as the metabolic requirements of tissue distal to the 
occlusion. The brachial artery is often occluded at the origin of the deep brachial or at the 
bifurcation into ulnar and radial arteries.[52] If the occlusion occurs proximal to the deep 
brachial artery origin, the arm usually presents with ischaemic signs and symptoms due to 
a lack of collateral blood supply. Conversely, the collateral blood supply for an occlusion 
distal to the deep brachial artery is profuse (including the deep brachial, superior and 
inferior ulnar collateral arteries as well as the cubital vessels), hence the clinical picture is 
commonly less severe. Occlusion of either the radial or ulnar arteries is not markedly 
injurious. However, occlusion of the more distal deep palmar arch can result in tissue 
necrosis.  
 
4.2.2) Embolic disease: Non-valvular origins of cardio-emboli 
Cardio-embolic sources can be of valvular or non-valvular origin. By far the most common 
non-valvular cause, is atrial fibrillation. Due to the erratic, uncoordinated contraction of 
the atria, a variable amount of static blood occupies the atrial appendage, predisposing to 
thrombus formation. Part of this thrombus may gain entry to the systemic circulation, 
resulting in systemic embolization. 
 
Ischaemic conditions of the myocardium can manifest with cardio-embolic events. This 
may present in the acute setting due to an acute myocardial infarction complicated by a 
dramatic increase in afterload (also referred to as “pump failure”) or in a delayed fashion 
by presenting with ischaemic cardiomyopathy. In both conditions, pooling of near-static 
blood within the chambers lead to thrombus formation. A small percentage follows acute 
myocardial infarction, be it clinically apparent or occult (also referred to as a silent 
myocardial infarction or SMI). SMI is not an infrequent event, with an incidence of 1-4% 
in the non-diabetic population and 10-20% in diabetic patients. The pathogenesis is 
incompletely understood, but thought to be sequelae of diabetic autonomic neuropathy.[56-
57] This condition should always be borne in mind, especially when confronted with
diabetic patients. 
Atrial myxoma is the most common benign tumour of the heart, representing 
approximately 50% of all cardiac tumours. Clinical manifestations are determined by the 
location, size and mobility of the tumour. Possible presentations include cardiac 
obstruction, arrhythmias and peripheral embolization. The embolization of tumour 
fragments or thrombotic material covered with tumour cells, occur in approximately 30% 
of myxoma patients.[58,60] Most of these tumours embolize to the central nervous system, 
resulting in ischaemic cerebrovascular incidents. Secondary embolization to the coronary 
arteries, kidneys, intestines and peripheral arteries have been described.[61] Among 4396 
reports of myxoma in the literature,[59] only 10 cases of atrial myxoma, complicated with 
AULI, have been reported. Even though rare, an embolizing myxoma should be included 
in the differential diagnosis of a young, otherwise healthy patient presenting with acute 
arterial ischaemia.[62] 
Various forms of interatrial communications, such as patent foramen ovale (PFO) and 
atrial septal defect (ASD), occur in a significant proportion of the general population. In 
an autopsy study of 965 hearts from normal people spanning an age range of 10 decades, 
the overall incidence of PFO was 27%.[63] The earliest documentation of paradoxical 
 
embolism through a PFO, was in the 1877 text of Julius Cohnheim. In more modern times, 
a group of investigators based in Paris, France first postulated an important role for PFO’s 
in young patients (younger than 55 years of age) with cryptogenic stroke based on a case-
control study.[64] 
 
The mechanistic model of systemic embolization caused or facilitated by a PFO, is 
paradoxical embolism. Venous clots and rarely other particles (such as air, fat, amniotic 
fluid, tumor emboli or emboli from right heart endocarditis), pass from the systemic 
venous circulation to the arterial circulation by means of a variable right-to-left shunt. The 
clinical diagnosis of paradoxical embolism relies on the concurrence of arterial embolism, 
venous thrombosis, interatrial communication and a gradient favouring right-to-left 
shunting.[65] This gradient occurs transiently in normal individuals during early ventricular 
systole as well as the strain and release phase of the Valsalva maneuver. During the 
straining phase the right atrial pressure rises disproportionately, followed by a sudden 
increase in systemic venous return to the right atrium in the release phase.[66] 
 
4.2.3) Embolic disease: Valvular origins of cardio-emobli 
Few complications of valvular heart disease can be more devastating than systemic 
embolism. Causes include rheumatic heart disease, bacterial endocarditis and sequelae of 
valve replacement surgery.  
 
The incidence of systemic embolism in rheumatic mitral valve disease (mitral stenosis 
and/or mitral regurgitation), is greater than in any other form of valvular heart disease and 
increases dramatically with the development of atrial fibrillation (AF).[67]  The risk of 
systemic emboli in rheumatic mitral valve disease is also greater in older patients[68-71] and 
those with lower cardiac indices,[68]  but appears to correlate poorly with mitral 
calcification[67]  and mitral valve area.[68] 
Clinically detectable systemic emboli in isolated aortic valve disease, are uncommon. The 
small, but consistent frequency of systemic emboli reported in earlier studies of aortic 
valve disease, may best be explained by unrecognized mitral valve disease, ischemic heart 
disease or coexisting AF. However, one centre  emphasized the thrombo-embolic potential 
of severe calcific aortic valve disease by  histologically demonstrating micro-thrombi in 
10 of 19 calcified and stenotic aortic valves.[72] It appears, therefore, that calcific micro-
emboli from heavily calcified aortic valves are not as rare as previously thought, but rather 
difficult to detect due to their small size (unless visualized in the retinal artery).   
With the advent of effective antimicrobial therapy, the incidence of systemic emboli in 
Infective Endocarditis (IE), has decreased. In the pre-antibiotic era, clinically detectable 
emboli occurred in 70 to 97% of patients with IE.[74]  Recent reports suggest figures in the 
region of 12 to 40%.[75-80] The use of echocardiography was met with great enthusiasm, in 
order to identify the patient at risk of embolization.  Initial reports proposed a high 
correlation between echocardiographically demonstrable vegetations and embolism.[81-84]
However, in a more recent review of this subject, one centre reported that 80% of patients 
with IE  had echocardiographic evidence of vegetations, while only one third had features 
of systemic emboli.[85]  
The patient with prosthetic valve endocarditis deserves special mention. With the 
exception of patients with bio-prostheses in normal sinus rhythm, patients with prosthetic 
valves are at a constant risk of thrombo-embolism, emphasizing the importance of 
uninterrupted anticoagulation therapy. The risk of thrombo-embolic events in prosthetic 
valve endocarditis are higher than in native valve endocarditis, approaching 50-88%.[86,87]
4.2.4) Embolic disease: Extra-cardiac origins 
An extra-cardiac source of emboli is nowadays identified in 5–12% of patients presenting 
with peripheral embolic disease. Aneurysms are the most common extra-cardiac source of 
peripheral emboli, followed by ulcerated atherosclerotic plaque rupture and disruption, 
leading to macro-embolization of plaque components (athero-embolism) or micro-
embolization of platelet aggregates. Systemic athero-embolism may present in any of 
three clinical forms: 
 The asymptomatic form, not diagnosed during the subject’s lifetime, but
recognized at autopsy.
 A benign form, such as blue toe / digit syndrome or cutaneous livedo, with a
relatively good prognosis if managed correctly.
 A diffuse multi-systemic form with a poor prognosis.
Although less commonly encountered, a few interesting disease processes may manifest 
with peripheral arterial embolism. These include entrapment syndromes of the peripheral 
arteries, congenital anomalies of the aortic arch as well as occupational / recreational 
diseases. 
 
4.2.4.1) Arterial thoracic outlet syndrome (ATOS) 
Historically, when Adson first described his manoeuvre in 1927,[89] thoracic outlet 
syndrome was called scalenus anticus syndrome. The underlying abnormality was thought 
to be compression of the subclavian artery (SCA) by the anterior scalene muscle (ASM). 
Approximately 30 years later, it was recognized that in addition to the SCA, the 
subclavian vein or brachial plexus can also be compressed and that structures other than 
the ASM, were also implicated in compression. In 1956, Peet et al renamed the condition 
by coining the all-inclusive label, thoracic outlet syndrome (TOS).[90] 
 
Throughout the course of medical history, TOS has developed a reputation as a condition 
based on convoluted neurological and vascular symptoms. Physicians have continually 
disagreed about the relevance and pathogenesis of TOS, leading to a wide spectrum of 
opinions and research directions. This disagreement is augmented by the presence of 
anatomic anomalies and abnormal diagnostic tests observed in an asymptomatic 
population, resulting in further dispute about the specificity and sensitivity of commonly 
used diagnostic tests.[91] 
 
Thoracic outlet syndrome describes a variety of symptoms caused by compression of the 
brachial plexus or subclavian vessels, at the thoracic outlet. In the majority of cases, 
symptoms are neurological in nature, with pain and weakness resulting from C8 or T1 
nerve root compression. Arterial or venous symptoms resulting from compression are 
uncommon, accounting for 5% of cases in a large published series by Roos et al.[88]   
Anatomically, the thoracic outlet and corresponding area of neurovascular compression, is 
considered to incorporate 3 areas, namely the interscalene triangle, costoclavicular triangle 
 
and subcoracoid space (Figure 4).[92-93] Typically, the left and right SCA ascend into the 
neck before arching laterally towards the medial border of the ASM. They descend 
laterally from the lateral margin of the ASM towards the outer border of the first rib, at 
which point they become the axillary arteries.[94] There are many variations described in 
the literature concerning the course of the SCA relative to the ASM. These include the 
right subclavian artery passing anterior, within, or posterior to the ASM.[94-98] These 
variations may occur because of a hypertrophied muscle, muscle strain or accompanying 
soft tissue abnormalities such as fibrosis or congenital bands.[99] Cervical ribs occur in 1–
6% of the general population and in approximately 10% of patients with TOS.[93,100-102]   
 
Figure 4: Schematic representation illustrating the anatomical relations of structures to 






















The list of causative mechanisms in TOS is extensive (Table 4), yet one of the earliest and 
most consistently described, is the presence of a cervical rib. Galen first documented the 
presence of cervical ribs in 2 AD and further elaboration by the anatomist Vesalius during 
the first dissections of human bodies in 1543, provided additional insight.[103-104]   
 
Table 4: Causative mechanisms described in  TOS 
Soft tissue lesions Bony lesions 
 
 
Scalene muscles + fibro-muscular bands 
 
Cervical rib (Complete / Partial) 
Subclavian muscle + costo-clavicular ligament First rib anomalies (Synostosis / Bifid) 




In a review of their experience with ATOS, the University of Natal reported the largest 
South African series to date.[105]  The most common bony lesion identified, was that of a 
compressed SCA between a cervical rib and the insertion of the anterior scalene muscle 
(See Table 5 for summary of findings). 
 
Table 5: Summary of underlying bony pathology encountered in ATOS.[105] 








  7 (+2 declined surgery) 




Partial cervical rib with fibrous band to scalene tubercle 
Osseous anomaly of 1st rib, articulated on 2nd rib 
 
 
The sequelae of a chronically compressed SCA represent the end stage of an undiagnosed 
condition. Compressive stenosis (postural or fixed) at the thoracic outlet develops with 
fibrous cuffing of the affected vessel, followed by post-stenotic dilatation (PSD) and 
 
aneurysm formation. Aneurysmal degeneration leads to mural thrombus formation and 
with it, risk of serial distal embolization (Figure 5). Most emboli are small and localized 
to the palmar and digital vessels, commonly presenting with Raynaud’s phenomenon. If 
unrecognized, severe digital ischaemia with digital ulceration or gangrene may occur. 
Although the genesis of PSD by wall vibration secondary to turbulent flow dynamics has 
been well studied, the natural history and clinical outcome of this chronic process is 
poorly understood, but certainly not benign. Experimental evidence suggests that PSD is a 
reversible phenomenon after release of the stenotic or compressive lesion. [106-107]  
 
Figure 5: Schematic representation illustrating the anatomical relations and sequelae of a 




tion of the arterial wall with distal thromboembolism, pseudoaneurysm formation or 
propagating dissection.[220] 
 
The axillary artery is vulnerable to compression as it passes beneath the tendon of the 
pectoralis minor muscle, where it is fixed at the origin of the circumflex humoral arteries. 
Repetitive vessel injury can lead to intimal hyperplasia and stenosis, aneurysmal degenera- 












By means of a retrospective analysis of 41 patients with objective findings of ATOS, 
Criado et al identified a spectrum of underlying arterial pathologies associated with this 
condition.[110] 
 
Table 6: Spectrum of arterial pathologies associated with ATOS  




        Number of cases  
     
Subclavian artery aneurysm                                                  12 
Postural stenosis with post-stenotic dilatation                                 10 
Postural stenosis with post-stenotic dilatation  
     Subclavian artery                5 
     Axillary artery                2 
Fixed subclavian stenosis                5 
Fixed stenosis with post-stenotic dilatation                 4 
Luminal filling defect                 2 
Subclavian artery occlusion  
 
               1 




Muscular hypertrophy (particularly of the scalene muscles) in athletes performing 
repetitive overhead activities (including weight lifters, swimmers and baseball 
players),[108] may put these athletes at risk of ATOS. Baseball pitchers and volleyball 
players are at particular risk of axillary artery injury due to repetitive and forceful arm 
elevation and extension. Male athletes appear to be at greater risk of axillary artery injury, 
with no gender-specific difference related to subclavian artery injury.[111] 
4.2.4.2) Quadrilateral space syndrome 
 
This syndrome usually affects athletes performing repetitive, strenuous shoulder activity, 
such as baseball pitchers and volleyball players. 
 
The quadrilateral space is formed by the teres minor (superiorly) and major (inferiorly), 
the long head of the triceps (medially) and the humerus (laterally) (Figure 6). After arising 
from the third part of the axillary artery, the posterior circumflex humeral artery (which 
can reach up to 8mm in size among major league baseball players)[112]  joins the axillary 
nerve as it traverses the quadrilateral space. At this point, structures are vulnerable to 
compression, particularly in the setting of hypertrophied surrounding muscles. 
Figure 6: Schematic representation illustrating the anatomical relations of the 
quadrilateral space, with particular reference to the posterior circumflex humeral artery 
and axillary nerve. 
Clinical presentation may include poorly localized discomfort within the shoulder girdle, 
paresthesia or numbness within the axillary nerve distribution or fatigue and weakness on 
Quadrilateral space 









extreme abduction and external rotation. Distal ischaemic symptoms may occur as a result 
of serial arterial embolization in association with aneurysm formation.  
 
Definitive diagnosis is made at arteriography by establishing position-dependant 
(abduction and external rotation of the shoulder joint) occlusion of the posterior 
circumflex humeral artery. 
 
4.2.4.3) Brachial artery entrapment 
Rarely, position-dependant ischaemia may occur during hyperextension of the elbow joint. 
Associated anatomical anomalies include the presence of a supracondylar spur with 
anomalous insertion of the pronator teres muscle, responsible for compression of the 
brachial artery.[113]  A case study of brachial artery entrapment exclusively due to muscular 
hypertrophy, have been reported.[114]  Although exceedingly rare, these conditions should 
be considered in patients presenting with atypical symptoms of ATOS.  
 
4.2.4.4) Hypothenar Hammer Syndrome (HHS) 
HHS is often overlooked in the absence of a thorough occupational and recreational 
history. Importantly, this condition is usually reversible through cessation of the offending 
activity, but can lead to morbidity and even amputation if not timeously recognized.  
 
Other terminology used to refer to an occupational disease triggered by continuous use of 
vibrating hand-held machinery, include hand-arm vibration syndrome (HAVS) and 
vibration white finger (now largely superseded by the broader concept of HAVS). HAVS 
refers to a disorder that affects the blood vessels, nerves, muscles and joints of the hand, 
 
wrist and arm. Injury can occur at frequencies between 5 and 2000 Hz, but the greatest 
risk exists between 50 and 150 Hz. HHS refers to the vascular component of HAVS. 
 
The concept of HHS was first described in 1934,[115-116] but the term ‘Hypothenar Hammer 
Syndrome’ was coined by Conn, after recognizing the mechanism of injury.[117] The 
incidence of HHS is remarkably low when one considers the relatively large segment of 
population exposed to the relevant occupational hazards. Possible explanations include 
anatomical variability of the vasculature in this region as well as the presence of 
subclinical disease. These factors may also explain the variable presentation of patients, 
ranging from asymptomatic disease to tissue necrosis.  
 
Although most commonly encountered within the work place (including carpentry,[117] 
motor mechanics and metal workers), HHS is not restricted to this environment. Recent 
case reports and case series have confirmed the presence of HHS in recreational and 
professional sport activities, including volley ball,[115] hockey,[115] mountain biking,[118] 
tennis,[119]  badminton,[120] weight lifting and baseball.     
 
The underlying pathogenesis of HHS is based on repetitive blunt trauma to a relatively 
unprotected terminal ulnar artery. After emerging from Guyon’s canal (between the 
pisiform and hook of the hamate), the distal ulnar artery becomes somewhat fixed as it 
runs superficially across the hypothenar musculature.[117]  Between its deep palmar branch 
and the origin of the superficial palmar arch, it is particularly vulnerable as it is only 
protected by skin, subcutaneous tissue, palmaris brevis muscle and superficial 
aponeurosis.[117,121]  Repetitive blunt trauma to the hypothenar eminence (Figure 8) 
 
compresses the ulnar artery against the hook of the hamate (the so called “hammer and 
anvil effect”), triggering vasospasm.[117,122,123] Trauma to the adventitial layer may cause 
thickening and fibrosis, ultimately leading to extrinsic scarring with post-stenotic 
dilatation / aneurysm formation or arterial occlusion.[117,121] Distal embolization of the 
digital arteries may exacerbate ischaemia.  
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Figure 8: Axial anatomy, demonstrating vulnerability of the terminal ulnar artery and 
accompanying nerve (sensory portion), to repetitive trauma (black arrow). (As depicted by 




4.2.4.5) Congenital anomalies 
Anatomical anomalies of the aortic arch and upper limb vasculature are rare occurrences 
(estimated frequency of 3%) that have been implicated in the pathogenesis and 
development of ischaemic conditions. These congenital anomalies may create stenoses, 
aneurysms (often manifesting as thrombo-embolism) and occlusive disease of the upper 
extremities, but are usually fortuitous radiological findings as it frequently follows an 
asymptomatic course.   
 
The most common aortic arch anomaly (as described by Hunauld in 1735) is the 
occurrence of a left aortic arch with an aberrant right SCA, seen in 0.5% of the 
population.[126] The vessel originates distal to the left subclavian origin (typically posterior 
and inferior on the arch) and crosses the midline between the oesophagus and vertebral 
Ulnar artery and nerve 
Radial artery  
Hook of hamate  
Hypothenar muscules  
Flexor retinaculum  
 
column (Figure 9). In 1794, Bayford described the first case of symptomatic compression 
of the oesophagus by the posteriorly positioned aberrant right SCA, known as dysphagia 
lusoria.  These patients may also have associated anomalies, such as a common carotid 
trunk and right vertebral artery originating directly from the right common carotid artery.  
 




Other, less common anomalies include the occurrence of a right aortic arch with an 
aberrant left SCA. Degenerative aneurysmal changes at its aortic origin may occur in up to 













































Variations in the arterial anatomy of the upper extremities, are uncommon and rarely 
cause ischaemia of the upper extremity in isolation. Most of these variants occur in either 
the radial or ulnar artery; brachial artery variations are less common.[127,128] Variability in 
the path or source of the radial artery is reported in up to 30% of patients. The most 
common variation is a high radial artery origin, arising from the brachial or axillary artery 
proximal to the antecubital fossa. This is estimated to occur in between 2% and 14% of 
extremities. Substantially less common variations include absence of the radial artery, 
duplication of the radial artery and superficial passage of the radial artery above the 
tendons of the snuffbox (adductor pollicis longus and extensor pollicis brevis). Variation 
in the ulnar artery pathway or position is much less commonly seen (3% to 5%).[129]  
The blood vessels in the hand communicate via 3 major arches—2 palmar and one dorsal 
arch. A great number of studies have elucidated the extreme anatomic variance in this 
network of vessels, particularly on the radial aspect of the hand. Studies demonstrate the 
superficial palmar arch to be complete in more than 80% of patients, with the deep palmar 
arch complete in more than 90%.[129] A clinically relevant anatomic variant is the presence 
of a communication between a persistent median artery (an embryologic remnant that 
normally undergoes apoptosis during upper limb development) and the superficial palmar 
arch, which serves to complete the arch. This was seen in 15.5% of specimens in a well-
performed cadaveric study.[130]  
 
4.2.5) Thrombotic disease 
Atherosclerosis of the upper extremity arteries is a relatively rare occurrence, leading 
some investigators to label all non-traumatic cases of AULI, as embolic. While this may 
hold true for a large proportion of cases, it fails to distinguish the rarer causes of arterial 
occlusion, such as native arterial thrombosis. The true incidence of thrombosis as a cause 
of AULI is difficult to determine. Reports suggest that 5% of AULI cases in population 
studies and 9–35% in surgical series are due to native artery thrombosis. Establishing the 
correct diagnosis is essential in order to offer appropriate management options. Treatment 
usually requires bypass surgery or thrombolytic therapy, with inappropriate embolectomy 
or thrombectomy associated with higher morbidity and mortality rates.  
 
Most of the proximal arterial lesions that cause emboli, can also result in thrombosis 
(including atherosclerotic plaques, aneurysms and arteritis). As Virchow suggested in 
1856, thrombus formation is the result of an interaction between an injured vascular 
surface, stasis and hypercoagulability of blood. Arterial thrombosis most often develops at 
the points of severe stenosis. However, a thrombus can form in the absence of significant 
pre-existing stenosis, particularly when the surface of the plaque is ulcerated or after intra-
plaque haemorrhage has occurred (vulnerable / unstable plaque). Low-flow 
haemodynamic states, such as congestive heart failure, hypovolaemia or hypotension of 
any cause may predispose to arterial thrombosis. Hypercoagulable states, such as 
myeloproliferative disorders, hyperviscosity syndromes and coagulation disorders, may 
also contribute to thrombosis of the diseased artery. 
 
 
5) THE ANATOMICAL BASIS OF DISEASE
On initial evaluation of this condition, it may be difficult to establish the precise aetio-
pathological process involved. Therefore, making use of a structured approach will be of 
benefit to the clinician. Some authors prefer classifying causes according to local, regional 
and systemic disease processes. Others categorize patients into two main groups, namely 
Upper Extremity Occlusive Disease and Thrombo-embolic Disease (refer to section on 
Aetio-pathology). 
As surgeons, an attractive approach to the myriad of underlying aetiologies, is the 
implementation of an anatomical framework. A differential diagnosis for each arterial 
segment can be compiled (Figure 10 below), but should be interpreted in terms of the 






Left ventricular aneurysm 
Left atrial myxoma 
Valvular 
Rheumatic mitral valve disease 
Left heart infective endocarditis 
Sequelae of cardiac valve  
  replacement 
Ascending aorta / aortic arch: 
Atherosclerotic stenosis / occlusion  / 
     degenerative aneurysm 
Aortic dissection (Stanford A) 
Takayasu’s arteritis (Type I, II or IV) 
Brachiocephalic / subclavian arteries: 
Atherosclerotic stenosis / occlusion  / degenerative 
     aneurysm 
Arterial TOS (Postural / fixed stenosis +- PSD or 
     aneurysm formation) 
Takayasu’s arteritis (Type I, II or IV) 
Fibromuscular dysplasia 
Congenital anomalies (absent proximal left SCA) 
Axillary artery: 
Atherosclerotic stenosis / occlusion  / 
     degenerative aneurysm 
Arterial TOS (Postural stenosis +- PSD or 
     aneurysm formation) 
Radiation induced vascular injury 
Thrombosed axillo-femoral bypass graft 
Brachial artery: 
Embolic occlusion (usually macro-emboli from 
     proximal source) 
Atherosclerotic stenosis / occlusion 
Thrombosed haemodialysis AV fistula / graft 
Congenital anomalies 
Ulnar and radial arteries: 
Buerger’s disease 
Embolic occlusion 
Atherosclerotic stenosis / occlusion 
Congenital anomalies (usually absent radial artery) 
Palmar arches: 
Buerger’s disease 
Embolization from proximal source 
     (usually micro-emboli)  
Occupational (HHS) 
Congenital anomalies (incomplete 
  superficial and /or deep palmar arch) 
Digital arteries: 
Buerger’s disease 
Embolization from proximal source (micro-emboli) 
Connective tissue disorders 
Vasculitis  
Occupational (HHS) 
Systemic venous circulation / 
right heart: 
Paradoxical embolism via PFO / ASD 
originating from: 
  DVT 
  Air-/fat-/amniotic-  or tumour emboli 
  Right heart infective endocarditis 
Figure 10: A proposed anatomical approach to the aetiology of upper limb ischaemia 
 
6) CLINICAL PRESENTATION AND MANAGEMENT PATHWAYS 
Clinicians prefer categorizing presenting patients into acute or chronic ischaemia, 
according to the duration of their symptoms. Acute ischaemia should be immediately 
assessed and the severity of ischaemia used to guide early management decisions.  
 
6.1) Acute upper limb ischaemia 
According to the TASC II consensus document,[11] acute limb ischemia (ALI) is defined 
as any sudden decrease in limb perfusion posing a potential threat to limb viability. 
Patients usually present within 2 weeks following the acute event, but time to presentation 
may be influenced by the severity of ischaemia and access to healthcare.[24] Clinical 
decision-making hinges upon a focused, but thorough history and clinical examination. 
Essential questions need to be answered pertaining to limb viability, the severity of 
ischaemia, suspected underlying aetiology, the presence of serious concurrent systemic 
diseases and conditions mimicking AULI.  
 
Limb viability 
An inappropriate attempt at revascularization of an irreversibly ischaemic limb, may result 
in preventable mortality. Signs that preclude limb salvage include the presence of 
compartmental rigidity and fixed skin staining (Table 6 – Rutherford category III).  A 
small number of patients present in a moribund state with signs of irreversible limb 
ischaemia. Terminal care may be the kindest and most appropriate management option in 
these patients. Primary amputation, after adequate resuscitation and stabilization, should 
be offered to candidates deemed fit for a general or loco-regional anaesthetic.  
 
 
Severity of ischaemia 
The severity of ischaemia can be accurately established by a systematic clinical 
examination and bedside doppler investigation. The duration, location and intensity 
(including change in the severity over time) of pain as well as the presence of motor or 
sensory deficiencies, guide early management decisions regarding the urgency of 
revascularization. Immediately threatened extremities should undergo an emergent attempt 
at revascularization, while a period of further investigation, observation and non-operative 
treatment may be appropriate in managing the marginally threatened limb. Rutherford et 
al[131] suggested a classification system (Table 7) in an attempt to standardize reports 
dealing with ALI.   
 
Table 7: Suggested classification of acute limb ischaemia[131]   
 
 Category Description/prognosis Sensory loss 
 
 






       
I Viable Not immediately threatened None None Audible Audible 






Salvageable if promptly  
treated 



















       
III Irreversible Major tissue necrosis or  
permanent nerve damage 
Profound, 
insensate 
Profound, paralysis Inaudible Inaudible 
       
 
Suspected underlying aetiology 
Importantly, the clinician should attempt to distinguish embolic from thrombotic 
occlusions, considering that management pathways differ considerably. Typically, the 
patient that presents with an embolic occlusion will do so early (usually within 24 hours) 
due to a lack of arterial collateralization and often present with a more severe grade of 
ischaemia.  
Thrombotic occlusions present later, usually within days of the acute event. One 
particularly important implication, is the relative ineffectiveness of thrombolysis in the 
management of thrombosis present for more than 2 weeks duration (as per post-hoc 
analysis of the STILE trial data).[132] It is important to enquire about a history of arm 
claudication and previous revascularization procedures. Signs of atherosclerotic occlusive 
disease of the contralateral upper extremity, favour the diagnosis of thrombosis.  
Serious concurrent diseases 
The identification of serious systemic illnesses in patients with AULI, is important for 
several reasons. Poorly optimized systemic diseases (including hypertension, diabetes, 
ischaemic heart disease / recent cardiac events and renal dysfunction), can influence the 
patient’s fitness for a general or loco-regional anaesthetic, contribute to the underlying 
disease process and drastically affect the patient’s prognosis. This can be best appreciated 
in the subgroup of patients presenting with embolic disease of the upper extremities. 
Deguara et al[1] reported, in a subgroup of patients that underwent embolectomy, that all 
early (30 day) mortalities were attributable to cardiopulmonary incidents, none being a 
consequence of arm ischemia or gangrene. The majority of patients (84%) with embolic 
disease had associated ischaemic heart disease or a recent myocardial infarction and 
between 51 - 63% was diagnosed with atrial fibrillation. The higher mortality rate of 
patients undergoing a seemingly small surgical procedure under general anaesthesia 
compared with loco-regional anaesthesia, may also reflect an increased risk of 
cardiovascular events. 
 
Conditions mimicking AULI 
Though AULI may often be an easy diagnosis to make, one has to consider certain 
conditions that may mimic or influence patient presentation. These include systemic shock 
/ low flow states (especially if associated with chronic occlusive disease), subclavian-
axillary vein thrombosis presenting with phlegmasia cerulea dolens, acute cervical 
compressive neuropathy and exertional forearm compartment syndrome.  
 
 
Non-operative vs operative management  
Individual events of AULI, are not usually as limb-threatening as those in the lower 
extremity and thrombo-embolectomy is not always required for limb salvage. AULI may 
be managed by implementing various treatment modalities, but no real guidelines exist to 
clarify when a conservative approach is warranted. Previous publications suggest that 
conservative management of patients with AULI results in functional limb impairment in 
50 – 75% of cases and is therefore not advocated.[52,133] Recent publications have 
challenged this view by highlighting several case series reporting successful conservative 
management in a selected subgroup of patients, with excellent functional outcome. 
Conservative management takes advantage of the superior collateral arterial supply in the 
arm, compared with the lower extremities. 
 
The best level of evidence on this topic, takes the form of a recently performed systematic 
review.[134] Conservative therapies included anticoagulation, rehydration and treatment of 
contributing medical conditions. A total of 34 retrospective studies and 3 review articles 
were recovered. Operative management was performed most commonly (86%), followed 
by conservative management (11%) and interventional radiological approaches (3%). 
 
Catheter-directed embolectomy procedures, when performed as the primary treatment 
modality, revealed an overall success rate of 85%–90%. Significant selection bias and 
treatment inconsistencies in the subgroup of patients receiving conservative management, 
hampered the interpretation of results. The perused literature only reported the use of 
conservative management in patients deemed to be unfit for surgical management or those 
with symptomatically mild disease, not considered worth treating. On worsening of 
symptoms, patients initially treated conservatively, were crossed over to the surgical 
intervention group. Furthermore, some patients were managed supportively without the 
initiation of anticoagulants. In those studies where anticoagulants were initiated, long-term 
anticoagulation rates were poor with some authors reporting a 22% effective 
anticoagulation rate in patients representing with recurrent embolism.[135]. 
 
When considering the evidence, it is clear that inherent challenges do exist. Significant 
numerical and ethical dilemmas may arise when attempting to perform a randomized 
controlled clinical trial to attain level-one evidence. The tendency to treat ‘‘fit’’ and 
‘‘unfit’’ patients differently, is deeply ingrained in clinical practice and it may be viewed 
unethical to deny a ‘‘fit’’ patient operative therapy in view of the current literature.  
 
Some authors believe that an initial conservative approach in suitable patients, are 
practiced more commonly than is reported. This underreporting limits the literature’s 
ability to report progress and when combined with selection bias, leads to poor quality 
data. Therefore, units regularly practising a non-operative approach to the acutely 




Series that combine both acute and chronic ischaemia are rare.[1,5-7] The largest of these, 
included 172 patients undergoing revascularization procedures for upper limb ischaemia 
over a 20 year period.[1] About two-thirds of the procedures were performed for acute 
ischaemia, with embolic disease being the most common underlying pathology in this 
subgroup, closely followed by trauma. More than half of the patients presenting with 
chronic ischaemia had an intrinsic atherosclerotic stenosis or occlusion of the subclavian 
or axillary artery, with the rest made up by thoracic outlet syndrome and iatrogenic 
injuries. 
 
7.1) Acute upper limb ischaemia: Embolic disease 
 
Numerous reports have been published with regard to outcome after lower extremity 
embolectomy. In contrast, few reports have focused on upper extremity embolic 
disease[53,136-141] with most of these only presenting early (30 day) outcome.[53,136-139] 
Generally, the functional outcome after upper extremity embolectomy is excellent, 
provided that there was minimal delay in presentation and severe ischaemia was not 
present at the time. However, early (30 day) mortality remains high, mostly as a result of 
severe comorbid disease.  
 
The concept that mortality following embolectomy is a consequence of the patient’s 
comorbidity rather than the embolus itself, is well supported.[1,52] Throughout the 
literature, it is generally agreed that patients who present with acute embolic episodes, 
have a high early (30 day) mortality rate ranging between 9 – 19%.[1,138,142,143] Deguara et 
al[1] reported a 30-day mortality rate of 18.2% in patients undergoing upper extremity 
 
embolectomy (n = 10). All deaths were attributable to cardiopulmonary events. A further 
11 patients died within a year of surgery, resulting in a 12-month mortality rate of 38.2% 
(n = 21). In a retrospective single centre study of 148 patients admitted with acute upper 
limb ischaemia, Licht et al reported that the cause of death was mostly due to 
cardiovascular (32%) and cerebrovascular (22%) incidents with 8% of patients dying from 
malignancy during the 5 year follow-up period.[142] 
 
These high mortality rates are convincing of poor short-term outcome, however, the 
relative paucity of long-term follow-up data led some authors to question whether this 
phenomenon persist after discharge from hospital. This was addressed by a National 
Cohort Study in Denmark, published in 2010, that followed 1 377 patients after thrombo-
embolectomy for a period of 5 to 17 years. Age- and sex-specific risk of stroke was 2 to 
16 times higher and risk of death 3 to 11 times higher than that of the general 
population.[143]  
 
Specific populations have been described, where the outcome is even worse than 
mentioned above. Javid et al[144]  reported on the outcome of 20 patients with an 
underlying malignancy and arterial thrombosis. The outcome was generally poor. Two 
patients underwent major amputations. The mortality rate from the time of presentation 
was 50% at 3 months and 83% at 12 months. Therefore, arterial thrombosis should 
probably be viewed as an agonal event in many of these patients and palliative treatment 




Authors generally agree that prompt operative intervention is the single most important  
determinant of a successful functional outcome. Be that as it may, some reports claim that 
the duration of symptoms before embolectomy does not significantly impact on functional 
outcome.[136,142] Licht et al[142] disclosed that  26% of patients in their series were treated 
more than 24 hours after the onset of symptoms and that the time interval between 
symptom onset and revascularization, did not significantly influence long-term result as 
measured by arm-function (Table 8; Chi-square = 3.9 with p = 0.42 between the three time 
intervals).  
 
Table 8: Relationship between arm-function and duration of ischaemia (Licht et al)[142]  
 





     
Less than 12h  33 (87%) 4 (11%) 1 (2%) 38 
12-24h 13 (93%)           1 (7%) - 14 
More than 24h 11 (69%) 4 (25%) 1 (6%) 16 
Total 57 (84%) 9 (13%) 2 (3%) 𝟔𝟖 
     
 
It may be argued that analysis of the length of ischaemia and arm function does not take 
into account the severity of ischaemia. Thus, patients who presented after 24 hours may 
have had less severe ischaemia than those who presented earlier because of pain. Even 
though one should aim to operate promptly in these patients in order to minimise potential 
functional compromise, the time interval per se should not be seen as a contra-indication 
to surgery. The extremity should only be regarded as being out of therapeutic reach if the 





7.2) Acute upper limb ischaemia: Thrombotic disease 
Few studies report the use of thrombolytic therapy in AULI, even though it’s role in the 
lower extremities has been well established.[145] When studies commenting on the use of 
thrombolytics in AULI are considered, thrombolysis and surgery have equal efficacy, but 
small numbers mitigate this conclusion.[146-148] Cejna et al[147] also found thrombolysis to 
have equivalent results to surgery, with the exception of distal occlusions, where results 
were found to be inferior. Concerns regarding the use of thrombolytics in AULI revolve 
around the risk of haemorrhagic cerebro-vascular incidents. Some authors suggest that this 
risk may be higher with upper than lower extremity thrombolytic therapies.  
 
7.3) Chronic upper limb ischaemia – Bypass procedures in general 
Upper limb arterial bypass procedures were first described by Garret in 1965. Since then, 
only a few small surgical series have reported their single centre experience with this 
procedure (Table 9).  
 
Table 9: Summary of major publications on upper limb bypass procedures 
 
 Publication Study group Tissue loss as 
indication 
     Key results 
    
Spinelli F et al[23]   





35% Primary patency 82.6%, 
Secondary patency 91.3%, Limb 
salvage 100% 
Hughes K et al[9]  






15% Primary patency 85%, Secondary 
patency 85%, Limb salvage 100% 
Chang BB et al[149] 






83% Primary patency 88.8%, 
Secondary patency 88.8%, Limb 
salvage 88.8% 
Roddy SP et al[10] 





13% Primary patency 87%, Secondary 
patency 98%, Limb salvage 100% 
    
 
In general, the results achieved with upper limb arterial bypass procedures are satisfying, 
with reported graft patency rates of between 85-98% at 2 years. Multiple factors influence 
surgical outcome. Certainly the most important factor, the indication for surgical 
intervention, varied significantly between trials.  Spinelli et al reported tissue loss as the 
indication in 83% of patients compared to 13% reported by Roddy et al. Other indications 
included exertional arm pain (Roddy et al 30%; Hughes et al 55%) and rest pain (Roddy et 
al 57%; Hughes et al 30%). Units, implementing a more aggressive approach to the 
management of relatively minor symptoms, may reflect better surgical outcomes, 
especially superior limb salvage rates.  
 
In stark contrast with the subgroup of patients presenting with embolic upper limb disease, 
none of the recent surgical bypass series (Spinelli et al 2010, Hughes et al 2007) reported 
any perioperative deaths, cardiac complications, wound infection, pulmonary 
complications or renal failure. The mean length of post-operative hospitalisation was 3- 6 
days. 
 
7.4) Chronic upper limb ischaemia – Distal bypass procedures 
A systematic review of 16 publications reporting on distal (infra-brachial) upper extremity 
bypass procedures, was recently performed.[150] At an average follow-up of 37 months, the 
overall autologous vein graft patency rate was 85% and autologous arterial (including 
deep inferior epigastric artery; lateral femoral circumflex artery and thoraco-dorsal artery) 
graft patency rate 100%.  All studies reported an improvement of ischemic symptoms 
including a reduction in cold sensitivity, pain and digital ulceration.  
 
 
7.5) Chronic upper limb ischaemia – Endovascular procedures 
The endovascular management of upper extremity atherosclerotic occlusive lesions, are 
being progressively explored. Current evidence seems to favour the use of percutaneous 
techniques in the management of occlusive disease of the supra-aortic trunks, while the 
treatment of infra-brachial lesions are still controversial.   
 
The technical success rate of open surgical BCA/SCA revascularization is high, but major 
complications may occur (13-19% incidence) with an expected 30 day mortality rate of 2– 
3%.[151-154] Multiple publications suggest similar success rates with less morbidity and 
mortality, when implementing percutaneous revascularization techniques to address 
occlusive lesions of this arterial segment.[151-154]  
 
Table 10: Summary of studies reporting on SCA / BCA stent placement 
 






Restenosis 1◦patency 2◦patency 
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1999[157]  
 



















Patel et al. 
2007[155] 
170 166 SCA, 11 
BCA 




        
 
Patel et al[155] recently published their experience with primary percutaneous 
revascularization of symptomatic BCA/SCA atherosclerotic lesions. This series is the 
largest to date, with 170 consecutive patients treated over a 13 year period. The technical 
 
success and patency rates were comparable to previously published reports, however, 
technical success in recanalizing occlusions (90.5%) were significantly higher than 
reported by prior studies. The author attributes this to the evolution of recanalization 
techniques, with 62% of patients with occlusions undergoing a retrograde brachial 
approach or combined femoral/brachial approach. Complications were reported in 5.9% 
(n=10) of patients with no procedure-related deaths recorded. This compares favourably 
with surgical series.[151-154]   
 
Literature on the endovascular management of radial and ulnar occlusive disease, are 
currently limited to case reports and small case series. [156-157] From this limited pool of 





























The objective of this study was to comprehensively review the Vascular Surgery Unit’s 
experience with upper limb ischaemia over a 12 year period by defining the pattern and 
distribution of disease and pathological profile, describing key demographic and clinical 
features and reporting on conventional clinical outcomes (including mortality, morbidity, 
limb salvage and re-intervention rates). These findings were interpreted in context of the 
current literature in order to identify potential areas of interest, perhaps paving the way for 

















1) STUDY DESIGN 
Retrospective descriptive study 
 
All patients that underwent a surgical intervention for upper limb ischaemia at Groote 
Schuur Hospital’s Vascular Unit between January 2000 and December 2011, were 
included in the audit. Approval from the Department of Surgery Research Committee and 
Faculty of Health Sciences Human Research Ethics Committee was obtained prior to 
accessing data (Appendix 1 & 2). A research folder was compiled for each patient and 
numeric codes assigned in order to maintain patient confidentiality. On completion of the 
data collection process, both qualitative and quantitative data were analyzed and 
comparisons made to the current literature. Interesting observations were highlighted and 
discussed in monograph form. 
 
2) STUDY PARTICIPANTS 
Sample selection 
All patients that underwent a surgical intervention for upper limb ischaemia from 2000 to 
2011, were retrospectively selected from the Groote Schuur Hospital Vascular Unit’s 
operative database.  
Inclusion criteria 
 Patients that underwent  revascularization and ablative procedure(s) for 
upper limb ischaemia at Groote Schuur Hospital’s Vascular Unit 
 Procedure(s) performed from  January 2000 to December 2011 
 Primary as well as secondary procedures 
 
Exclusion criteria 
 Penetrating and / or blunt traumatic vascular injuries  
The Trauma Unit at our facility published extensively on this topic (including brachial, 
axillary and subclavian artery injuries[160-162]  – a total of 242 patients) between 2003 and 
2011. In order to guard against the duplication of data, this subgroup of patients were 
excluded from the current series. 
 Primary Raynaud’s phenomenon 
 
3) OUTCOME MEASUREMENTS 
Patient hospital records, in the form of a hospital folder or microfilms, were obtained from 
Medical Records Department and data electronically captured by means of a data 
collection sheet in Microsoft Word (Appendix 3).  Referral letters, clinical notes, 
treatment charts and special investigations (including laboratory results sheets in the 
folder) were perused. The NHLS Disa electronic results system was accessed for each 
patient to confirm that no laboratory investigations of significance, were overlooked. This 
process was performed by the researcher, under the following headings:  
 Demographic details 
o Age, gender and ethnic group 
 Contact details 
o Address and telephone number of patient or relative 
 Clinical presentation 
o Acute limb ischaemia 
 Rutherford grade I, IIa, IIb or III, with or without the presence of 
compartment syndrome 
 
o Chronic limb ischaemia 
 Digital ulceration (active or healed), Raynauds phenomenon, 
claudication symptoms or neuro-vascular symptoms 
 Risk factor(s) for atherosclerosis 
o Hypertension, hypercholesterolaemia, Diabetes mellitus (Type I/II) and 
cigarette smoking (including estimated pack years) 
o Other substances (including cannabis and TIK) 
 Other systemic diseases 
 Appropriate medical therapy 
o Pre-event as well as post-event 
 Underlying aetio-pathology 
o Embolic source 
 Cardiac or extra-cardiac (including site of occlusion) 
o Thrombotic source 
 Associated with atherosclerosis or thrombophilia (including site of 
occlusion) 
 Special investigations performed 
o Upper limb dopplers, upper limb duplex arteriogram, digital doppler 
pressure with caloric stimulation 
o Angiogram (Arch or select run) 
o MD-CTA, MRA 
o CXR / C-spine X ray 
o Echo / ERNA 
 
o Laboratory investigations 
 S-fibrinogen, CRP and ESR, fasting homocysteine level, S-
creatinine, HIV status 
 Procedure(s) performed 
o Date and length of procedure, time started (within day time or after hours) 
 Open surgical procedure 
o Embolectomy, bypass graft (including type), fasciotomy performed, 
ablation performed (including before or after attempt at revascularization 
and level of amputation) 
 Endovascular procedure 
o PTA, stentgraft placement (including type and site), thrombolysis (alone or 
as combination therapy) 
 Peri-operative (30 day) and follow-up (6 months, long term) data 
o Died / Alive (including reason for death) 
o Systemic complications 
o Procedure related complications 
 Wound complications, bypass graft complications, neuropraxia / 
nerve injuries and ablation  
o Pulse status / Doppler pressures / Duplex arteriogram 
 Improved, same or deteriorated 
o Function 
 Normal, weakness, contracture, claudication 
 
 
A clinical research folder was compiled for each patient and numeric codes assigned in 
order to maintain patient confidentiality. The research folder included the afore mentioned 
Microsoft Word data collection sheet, copies of referral letters, results from special 
investigations performed as well as operation sheets.  
 
4) DATA ANALYSIS 
On completion of the data collection process, data was transferred from the patient 
research folders and consolidated in a Microsoft Excel data collection sheet. The data 
was appropriately coded to assist data analysis. Data analysis was performed using 
STATA®  statistics / data analysis program by StataCorp, Texas, USA.  Frequencies and  
percentages were calculated for categorical data. Means and standard deviations or 














When dealing with a broad topic and, in the absence of a specific question being asked, 
presenting findings in an isolated fashion may be less informative to the reader. Therefore, 
although slightly unconventional, the results of this study will include concise, relevant 
discussion of the literature in the interest of capturing the true context of these findings. 
The “discussion” section (chapter 6) will focus on future research perspectives. 
 
2) INCIDENCE AND DEMOGRAPHICS 
Sixty-four patients presenting with upper limb ischaemia, were evaluated and managed 
surgically during the 12 year study period (from 01 January 2000 to 31 December 2011). 
As previously mentioned, referrals managed non-surgically, were excluded from this 
series. Therefore, Figure 11 should not be interpreted as the total number of referrals 
received, but as the number of referrals warranting surgical intervention.  
 






















A clear escalating trend was observed, with 56% of surgically managed patients, referred 
within the last 4 years of the study period (2008-2011). Seeing that subjects were 
retrospectively selected from an operative database, no data pertaining to the total number of 
referrals were captured. Therefore, no correlation can be made between the number of 
referrals received and the number of patients managed surgically. Regardless, an increase in 
the absolute number of referrals is still the most conceivable explanation to rationalize the 
observed trend. This finding, however, needs to be interpreted in context of the population 
growth within the Western Cape during the study period and does not necessarily represent a 
true increase in disease incidence (Figure 12).  
 
Figure 12: Western Cape population growth according to recent Census statistics 
 
Census year 
Another, less likely explanation may be that a more aggressive surgical approach (or more 
guarded approach to non-operative management) was followed during the last 4 years of 
the study period. Anecdotally though, the indications for surgical intervention has 



























Age and gender 
Forty females (62.5%) with a mean age of 51 years (range 15 – 84 years) and 24 males 
(37.5%) with a mean age of 46 years (range 15 – 76 years), were included in the study, 
reflecting a male to female ratio of 0.60. Comparatively, the 2011 Western Cape Census 
figures reported a male to female ratio of 0.96, drastically higher than that of the study 
group.  However, one has to be mindful of the fact that demographic variables may be 
strongly influenced by the underlying cause of ischaemia (Table 11).  
 
Table 11: Comparative demographic details according to prevailing aetiologies 
   Aetiology  N of patients   Mean age (range)  M:F ratio 
 
     
   Thrombo-embolic disease 30  55 (37 – 80) 0.43 
   Atherosclerotic occlusive disease 12  57 (39 – 84) 0.71 
   Thoracic outlet obstruction 8  28 (15 – 59) 1.67 
   Takayasu’s disease 4  27 (20 – 36) 0.33 
   Thromboangiitis obliterans 4  46 (36 – 53) 3.00 
     
 
Considering that we are dealing with an aetiologically heterogeneous group of patients, 
significant demographic findings should rather be discussed in context of the underlying 
cause of ischaemia.  
 
Embolic versus UEAOD 
Multiple publications support the view that patients with thrombo-embolic ULI, when 
compared to UEAOD, present at a more advanced age.[1,163] One of these series included 
172 patients undergoing revascularization procedures for ULI over a 20 year period.[1] The 
mean age of presentation in the thrombo-embolic subgroup (n=61) was appreciably older 
(72.4 years) than those presenting with UEAOD (n=29, mean age 62.5 years). 
Interestingly, this finding was not observed in our series, with the thrombo-embolic 
 
subgroup (n=30) notably younger than expected (mean age of 55 years) compared to the 
subgroup presenting with UEAOD (n=12, mean age of 57 years). A larger proportion of 
females were affected by thrombo-embolic disease in our series, than reported by Deguara 
et al[1]. The reasons for these findings are still unclear and further investigation is 
warranted.  
Table 12: Demographic comparison of TED versus UEAOD subgroups 
 
                Current series 
  n           Mean age 
 
M:F ratio 
Subgroup                   Deguara et al 
n              Mean age 
 
M:F ratio 
       
      30     55 years    1:2.3 Thrombo-embolic     61 72.4 years 1:1.1 
      12     57 years    1:1.4 UEAOD     29 62.5 years 1:1.9 




Patients of mixed-race heritage contributed 48% to the study group, followed by 
Caucasians (27%), Blacks (23%) and Indians (2%). Once again, it is important to interpret 
these findings in terms of the 2001/11 Western Cape Census figures (Figure 13). 
Unfortunately, due to multiple confounding factors being present, no firm conclusions can 
be drawn regarding the race-specific incidence of ULI. One such factor is the unknown 
number a patients seeking medical attention from private health care facilities.  
 
Figure 13: Race prevalence 
















   Current  series 
 
 
   Census 2001 
 
 
  Census 2011 
                         Ethnic group 
 
Referral patterns 
As expected, the majority of cases (84%) were referred from health care facilities located 
within the Cape Metropole. Approximately 8% of patients were referred from centres 
outside of the Cape Metropole, but within the borders of the Western Cape with 2 patients 
referred from the Eastern Cape.  
 
Table 13: Source of referral according to province 




   Cape Metropole                           
                    
 
            
           54 
 
 
   84.4 
 
         
         
   Outside Cape Metropole 
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             3 
     3.1 
 
     4.7 
 
 
      100.0 
 
Most referrals were received from Secondary Hospitals (52%), with Community Health 
Centres (16%), Tertiary Hospitals (13%), Private facilities (13%) and Primary Hospitals 
(3%) contributing to the rest of the referrals. 
 
Table 14: Level of referring facility 












2   3.1 
Secondary Hopsital 
 







Unknown 3   4.7 
 
 
Table 15: Specific referring facility 
Facility 
 
n    Percentage    Cumulative  
 







  3.1 
 
Mitchell’s Plane CHC 2   3.1  
Retreat CHC 3   4.7  
Hanover Park CHC 3   4.7   15.7 
 
Primary Hospitals 








  3.1 
 
 
  18.8 
 
 
Conradie Hospital 2   3.1  
Victoria Hospital 9 14.1  
New Somerset Hospital 9 14.1  
GF Jooste Hospital 6   9.4  
George Hospital 5   7.8  





































  70.3 
 
 












3) RISK FACTORS  
Risk factors for atherosclerosis and the development of UEAOD 
Compared to previous publications reporting on the incidence of atherosclerotic risk 
factors in UEAOD, [9,23]  our series reflected small numbers (n=12).  
 
The most striking feature recognized was the disproportionately high prevalence of 
cigarette smoking (83%), almost double that reported by Spinelli et al[23]  (Table 16). 
 
Smoking history could be quantified from the clinical records in 8 out of 10 patients, with 
an average of 31 pack years.  
 
As previously mentioned, tobacco use is particularly prevalent in patients with upper 
extremity atherosclerotic occlusive disease (UEAOD) and seems to have a stronger 
causative association than diabetes, hypertension and dyslipidaemia. The above figures 
reaffirm the undeniable role played by cigarette smoking in the different manifestations of 
peripheral arterial disease as well as the importance of addressing this modifiable risk 
factor.   
 
Recently, substance abuse has been implicated in the process of accelerated and 
precocious atherosclerosis as well as Thromboangiitis obliterans (TAO). A history of 
substance abuse were present in 9% of subjects with 5 patients reporting regular cannabis 
use and 1 patient presenting with a complication of intra-arterial heroin injection.  
 
Hypertension was present in 50% of patients in the UEAOD subgroup, which compared 
well with the 2007 report by Hughes et al[9] (Table 16). Numerous authors (including 
Roddy[10] and Hughes et al[9]) have reported on the significantly lower incidence of 
diabetes mellitus in upper extremity bypass patients, compared to the lower extremity 
bypass population from the same centres. Nonetheless, our series estimated the incidence 
of diabetes mellitus to be 17%, much lower than suggested by preceding reports. In 
addition, 33% of patients were previously diagnosed with dyslipidaemia.  
 
 
The most recently published surgical series reporting on procedures performed for 
UEAOD, quote the following risk factor incidences: 
 
Table 16: Studies evaluating incidence of risk factors in atherosclerotic occlusive disease   
Study               n       Smoking(%) HPT(%)    DM (%) 
 











Spinelli et al, 2009 [23]    23 43 26 48 












Pharmacological modification of atherosclerotic risk factors 
After an in depth evaluation of clinical records (including referral letters, prescription 
charts and clinical admission notes), it was estimated that as many as 16 out of 60 patients 
(27%) were not receiving adequate pharmacological therapies aimed at addressing pre-
existing risk factors. The TASC II document (section B1.2)[24]  was used as a guideline to 
assess the appropriateness of pre-referral therapy. In 4 patients, clinical information 
regarding pre-referral treatment was insufficient in order to assess the appropriateness of 
medical therapy. 
 
Systemic comorbidities in the Thrombo-embolic subgroup  
The presence of serious concurrent illness in this specific patient group, impact greatly on 
clinical outcomes. Deguara et al[1] attributed all early (30 day) mortalities to 
cardiopulmonary incidents, none being a consequence of arm ischemia or gangrene. The 
majority of patients (84%) with embolic disease, had associated ischemic heart disease or 
 
a recent myocardial infarction and between 51 - 63% was diagnosed with atrial 
fibrillation.  
 
In the current series, 8 of the 30 patients (27%) had recent clinical, electrocardiographic, 
echocardiographic and / or angiographic signs of ischaemic heart disease. Four patients 
(13%) were in atrial fibrillation at the time of initial presentation. Intra-cardiac thrombus 
could be identified in one patient. These figures suggest that concurrent cardiac conditions 
might be underdiagnosed in our setting, however this needs to be interpreted in context of 
the demographic profile. One such demographic consideration is the difference in mean 
age of 17 years (current series 55 years; Deguara[1]  72 years) in the TED subgroup of 
patients, perhaps indicating a younger population with a lower risk of developing CAD. 
 
Other associated systemic diseases were pulmonary tuberculosis (5 patients), previous 
cerebro-vascular incidents (3 patients) and underlying carcinoma (3 patients – lung, breast 
and cervix cancer respectively). 
 
4) AETIO-PATHOLOGY 
The largest surgical series investigating patients undergoing revascularization procedures 
for ULI, was published by Deguara et al[1]  in 2005. A total of 172 patients were included 
over a 20 year period, with 53 cases related to upper extremity trauma (excluded in the 
current series). Comparison of data between the two series (Table 17 and 18), makes for 




Table 17: Summary of current series according to underlying aetio-pathology 























   Thrombo-embolic 30 (47%) 47 55 1:2.3 16.7 
   Arterial thoracic outlet syndrome 2 (3%) 5   - 
   Iatrogenic 2 (3%) 4   - 
   Polymyositis compartment    
        syndrome 
1 (2%) 1   - 
 
 
Chronic  29 (45%) 33 44 1:1.1 3.4 
 
   Atherosclerotic disease 12 (19%) 16 57 1:1.4 8.3 
   Arterial thoracic outlet syndrome 6 (9%) 6 28 5:1 - 
   Takayasu’s disease 4 (6%) 4 27 1:3 - 
   Thromboangiitis obliterans 4 (6%) 4 46 3:1 - 
   Occupational small vessel disease 3 (5%) 3 32 1:2 - 
      
 
 
Table 18: Summary of cases according to underlying aetio-pathology, by Deguara et al[1]   























   Thrombo-embolic 61 (35%) 68 72 1:1.1 18.2 
   Trauma 53 (31%) 54 33 5.6:1 3.8 
   Iatrogenic 2 (1%) 2 46 0:2 - 
      
      
Chronic  
 
56 (33%) 59    
   Atherosclerotic disease 29 (17%) 32 63 1:1.9 6.9 
   Subclavian steal syndrome   15 (9%) 15 63 2:3 - 
   Arterial thoracic outlet syndrome 8 (5%) 8 47 1:1.7 - 
   Iatrogenic 4 (3%) 4 51 1:1 - 
      
 
 
Ratio of acute to chronic presentations 
Despite the apparent disproportion of acute to chronic presentations in the Deguara group, 
the ratios are similar to the current series after exclusion of the trauma subgroup. The 
 
percentage of patients presenting with TED (current series 45%; Deguara et al 51%) and 
UEAOD (current series 18%; Deguara et al 24%) were similar in both series.  
 
Thrombo-embolic disease 
As expected, the majority of thrombo-embolic events resulted in occlusion at the level of 
the brachial artery (17 patients in total). Nine patients presented with higher occlusions (2 
subclavian artery, 7 axillary artery). Three patients had thrombo-embolic occlusions distal 
to the elbow (2 radial artery, 1 ulnar artery) and one patient presented with blue finger 
syndrome. Eyers et al[2], in an excellent review of this subject, collected data from 
multiple series in order to establish the most common level of arterial occlusion. Our 
series compare well with these figures (Figure 14).  
 
Figure 14: Comparative diagram (Eyers et al[2] vs Current series) translating the 
























In the current series, a left-sided predominance was noted across all levels of obstruction 
with a right to left sided ratio of 1:2. This is exceedingly unusual, as most authors describe 
a higher incidence of embolism affecting the right arm, probably due to the larger 
diameter of the BCA compared to the left SCA as well as the favourable angle that exists 
between the aorta and BCA.[4] 
 
Atherosclerotic lesions 
The subclavian artery was predominantly involved (8 patients), the axillary artery in 1 
patient and the brachial artery affected in 3 patients. Therefore, a clear proximal pattern 
was observed in this subgroup of patients. Once again, as observed in the thrombo-
embolic subgroup, clear left sided predominance was noted with a right to left ratio of 1:5. 
All subclavian lesions were left sided.  Morphologically, 6 lesions were described as 
stenotic, 5 as occlusions and 1 patient presented with thrombosis of a degenerative 
aneurysm. Unfortunately, it was not possible to accurately ascertain from clinical notes 
whether predominantly ostial, mono- or multi-segmental disease was present. 
 
Table 19: Summary of underlying arterial lesions in UEAOD subgroup 
Morphological lesion n 
 
 
     Stenosis 
 
     Occlusion 
 















Arterial thoracic outlet syndrome (ATOS) 
Eight patients developed upper limb ischaemia as a consequence of ATOS, of which 7 
(88%) presented with underlying bony pathology. This subgroup of patients was generally 
younger than patients presenting with thrombo-embolic or UEAOD, with a mean age of 
28 years (Table 11). Interestingly, two of these patients presented with AULI (Rutherford 
I and IIa), with 6 patients presenting with chronic symptomatology.  
 

















Muscular band 1 − 1 
 
Anomalous 1st rib − 1 1 
 






Four patients with Takayasu’s disease presented with chronic upper limb ischaemic 
symptoms. The mean age of the patients was 27 years with a male to female ratio of 1:3 
(Table 11). Three patients complained of upper limb claudication symptoms with one 
suffering two ischaemic cerebro-vascular incidents prior to presentation. Level of disease 
ranged from stenosis of the BCA with occlusion of its outflow (one patient) to proximal 
left CCA stenosis with associated left SCA occlusion (two patients). One patient presented 
with prosthetic graft sepsis complicated by an acute bleed from the right CCA anastomosis 
after previous aortic arch reconstruction for aneurysmal disease.   
 
Thromboangiitis obliterans  
Four patients with active digital ulceration due to Buerger’s disease, were evaluated and 
surgically managed during the study period. The mean age at presentation was 46 years 
and a male to female ratio of 3:1 was noted. The average smoking history was 36 pack 
years in this subgroup of patients. One patient acknowledged the regular use of cannabis 
in conjunction with cigarettes.  
 
Small vessel disease 
Two patients presented with active digital ulceration in combination with cold-related 
vasospasm and one with cold-related vasospasm alone. The mean age at presentation was 
32 years and the male to female ratio 1:2. The secondary associations were connective 
tissue disease (SLE), occupational (HHS) and atherosclerotic small vessel disease.  
 
Iatrogenic  
The unfortunate occurrence of iatrogenic compartment syndrome was diagnosed in two 
patients. One patient presented with ALI after tissue infiltration of a peripheral venous 
catheter (Rutherford IIa) and the other due to acute brachial artery thrombosis after arterial 
catheterization (Rutherford I).  
 
5) INITIAL CLINICAL PRESENTATION 
When considering the timing of symptom onset, 55% of cases were classified as acute 
ischaemia and 45% as chronic. On comparison of the current series (Table 17) with the 
Deguara group (Table 18), an apparent disproportion of acute to chronic presentations is 
noted. However, in order to compare the above data sets reliably, the trauma subgroup of 
 
patients had to be excluded as specified by the current series’ exclusion criteria. After 
exclusion, the ratio of acute to chronic cases was remarkably similar. (Current series 1.22; 
Deguara et al[1] 1.13). 
 
Thirty-five patients presented with AULI necessitating surgical intervention during the 
study period. Table 21 and Figure 15 further reflect relevant detail regarding the clinical 
presentation of these patients.   
Table 21: Summary of AULI presentations, according to severity of ischaemia 
Rutherford grade 
 












14 40 53 











    
 
 
Established compartment syndrome was present in 6 of the 35 AULI cases (17%) and was 
most prevalent in the Rutherford IIa group (8.6%). 























The majority of 29 patients with CULI, presented with signs of tissue necrosis (48%), 
including digital gangrene, active / healed digital ulceration.  Other presentations in this 
group included upper extremity claudication symptoms (31%), rest pain (14%) as well as 
neuro-vascular symptoms (7%). Figure 16 compares the above figures with that of other 
units.  
Figure 16: Summary of CULI presentations 
 
                                                 Clinical presentation 
 
6) SURGICAL INTERVENTIONS 
 
Overview 
Eighty-nine procedures were performed in 64 patients. Of these, 78 were open procedures, 
6 were managed via an exclusively endovascular approach and 5 patients underwent a 
combination of open and endovascular therapy.   A distinction should be made between 
minor procedures (20 in total, average operating time of 49 minutes) and attempts at 








Tissue necrosis Claudication Rest pain Neuro-vascular
Percentage 
(%) 
  Current series 
 
   Roddy et al[10] 
 
   Hughes et al[9] 
 
cases performed, it was possible to establish whether the procedure was performed in 
daytime hours (56%) or afterhours (44%).  
 
Minor and ablative procedures 
Most minor procedures were performed as secondary or tertiary procedures. These 
included wound debridements, evacuation of haematomas, closure of fasciotomy wounds 
and excision / ligation of bypass grafts.  
 
Figure 17: Summary of ablative and minor procedures performed 
       
 
Procedures performed for TED 












Number of  
procedures 
Ablative procedures Minor procedures 
 
Table 22: Breakdown of procedures performed for thrombo-embolic disease  
Procedure 
 






     Thrombo-embolectomy  17 
     Thrombo-embolectomy and fasciotomy  
     Intra-operative thrombolysis (Streptokinase x1, tPA x1)  
     Brachial-brachial  / -distal bypass (Autologous vein graft)  
     Catheter-directed thrombolysis (Streptokinase x1)                                        
     Stentgraft  placement (Fluency® 8x40mm) 
     Aortic arch reconstruction  (Gelsoft Dacron 8mm graft)                                                     
  7 
  2 
  2 
1 
  1 





     Above-elbow amputation    1 
   
Secondary procedures  10 
 
     Brachial-distal bypass graft    2 
     Re-embolectomy    1 
     Fasciotomy    1 
     Haematoma evacuation    1 
     Veinpatch angioplasty of veingraft    1 
     Below-elbow amputation    1 
     Digital amputation 
 
   3 
 
 
Procedures performed for UEAOD 
Twenty-seven procedures were performed in 16 patients. Twenty-one of these were open 
surgical interventions and 6 were exclusively endovascular. 
  
Open surgical procedures:  
Eleven bypass procedures were performed. These included 4 brachial-distal / -brachial 
bypass grafts (all performed using autologous reverse vein graft), 2 axillary-brachial 
bypass grafts (autologous reverse vein graft / autologous SFA graft in patient with 
previous lower limb ablation), 3 subclavian-axillary / -brachial bypass grafts (2 ePTFE 
6mm, 1 Dacron® 6mm) and 2 common carotid-axillary (PTFE 8mm) / -brachial bypass 
grafts (autologous reverse vein graft).  
 
Endovascular procedures:  
Lesions managed by endovascular means, were all located within the subclavian artery. 
Four lesions were primarily managed with bare metal stent placement (1 x Protégé® 8 x 
27mm self-expandable stent, 2 x Omnilink Elite® 8x39mm balloon expandable stent, 1 x 
Sinus-Flex® 8x40mm self-expandable stent) and one managed with self-expandable bare 
metal stent placement (Complete® SE 8x60mm) after failed PTA previously. A retrograde 
brachial approach at cutdown was used to address three of the lesions, with a trans-
femoral approach implemented in the remaining two cases. 
 









     Bypass procedures 11 
          Brachial-distal / brachial-brachial 4 
          Axillary-brachial  2 
          Subclavian-axillary / subclavian-brachial 3 
          Common carotid-axillary / common carotid-brachial 2 
 
     Primary amputations 4 
          Digital amputations 4 
 
     Secondary amputations 3 
          Above elbow amputations 3 
 
     Graft thrombectomies 2 
 
     Wound haematoma evacuation 1 
 
Endovascular procedures       6 
 
     Primary procedures  
          Subclavian artery balloon angioplasty 1 
          Subclavian artery stent placement (Protégé® 8 x 27mm, Sinus-Flex® 8x40mm, 
                                                                                         2 x Omnilink Elite® 8x39mm) 
4 
 
     Secondary procedure  




Procedures performed for arterial thoracic outlet syndrome (ATOS) 
Eight patients developed upper limb ischaemia as a result of thoracic outlet syndrome.  
 
Table 24: Breakdown of procedures in patients presenting with ATOS  
Patient                              1 
                     𝐩𝐫𝐨𝐜𝐞𝐝𝐮𝐫𝐞 
       2 
       𝐩𝐫𝐨𝐜𝐞𝐝𝐮𝐫𝐞 
     3 





    
1 
 
Thrombo-embolectomy, thrombolysis + 
fasciotomy 





Thrombo-embolectomy + fasciotomy TO decompression - 2 
3 
 







SCA-Axillary PTFE bypass + brachial-ulnar 
RSVG bypass  
- - 1 
5 
 
SCA-Axillary PTFE bypass - - 1 
6 
 
TO decompression - - 1 
7 
 
TE followed by SCA-Axillary PTFE bypass - - 1 
8 CCA-brachial Dacron® bypass + brachial-ulnar 
RSVG bypass + fasciotomy + primary digital 
amputation 




     
 
Two of these patients presented with acute upper limb ischaemia (Rutherford I and IIa), 
necessitating emergency surgical treatment in the form of thrombo-embolectomy 
combined with intra-operative thrombolysis (in one patient), followed by fasciotomy. The 
underlying lesions (muscular band and cervical ribs) were addressed during secondary and 
tertiary procedures.  
 
Six patients presented with chronic complaints. One patient was managed with primary 
thoracic outlet decompression and 5 patients underwent arterial bypass procedures 
combined with primary digital amputation where appropriate.  The bypass procedures 
performed included two CCA-brachial artery bypass grafts (reverse basillic vein graft, 
8mm Dacron® prosthetic graft) and three SCA-axillary artery bypass grafts (6mm PTFE 
 
prosthetic graft). In two of these patients, a further brachial-ulnar artery bypass was 
performed at the same sitting (reverse saphenous vein graft). One above elbow amputation 
was performed after failure of a CCA-brachial artery bypass procedure. 
 
Procedures performed for Takayasu’s disease 
Two patients underwent aortic arch reconstruction (14 x 7mm bifurcated Albograft®) for 
Takayasu’s disease and one received an axillary-axillary artery bypass graft (6mm PTFE 
ring-reinforced graft). One patient presented with a stenosis of the brachiocephalic artery 
at the origin, while two patients had symptomatic (L) SCA occlusion as well as 50% (L) 
CCA stenosis. One patient presented with graft sepsis that manifested with an acute bleed 




Five thoracoscopic sympathectomies were performed for upper limb ischaemia. A 
standard T2 ganglionectomy was performed with a video-assisted two port technique in all 
cases. The indications varied and included non-reconstructable small vessel disease 
(histologically confirmed to be Thromboangiitis obliterans), HHS, SLE vasculitis and 
atherosclerotic small vessel disease. The average operating time was 55 minutes and 







Surgical outcome measures were reported by quantifying the mortality, morbidity 
(including systemic and procedural complications) and amputation rates at different time 
intervals after the initial surgical procedure was performed. These intervals included 30-
day outcome, outcome on 6 month follow-up as well as long term follow-up (more than 6 
months after initial procedure). Unfortunately, follow-up appointments were poorly 
attended, especially affecting long term outcome results. 
 
30-Day outcomes 
Follow-up data could be accumulated in 53 of the 64 patients (83%). Eighteen 
amputations were performed in 64 patients, of which 6 were major amputations (above- or 
below-elbow level). Most amputations (n=10) were performed primarily, in patients 
presenting with irreversible tissue necrosis not justifying an attempt at revascularization. 
Eight secondary amputations (4 digital, 3 above-elbow and 1 below-elbow) were 
performed within 30 days of an initial attempt at revascularization. Two of these were 
performed following bypass graft occlusion. Therefore, the 30-day amputation rate after 
initial revascularization, was 12.5%.   
 
At 30-day review, 35 patients were evaluated by clinical palpation, hand-held doppler 
pressures and/or duplex arteriogram. These findings were compared to corresponding pre-
operative assessment, with patients being categorized into 3 groups. Deterioration of pulse 















Mortalities   
     Acute coronary syndrome 2  
     Acute renal failure 2  






Morbidities   
     Systemic complications    
          Acute kidney injury 
          Acute respiratory insufficiency 
          Acute coronary syndrome 














     Procedural complications    
          Surgical site haematoma 
          Superficial surgical site infection 
          Bypass graft occlusion 
          Pseudo-aneurysm post-angiogram 
          Delayed fasciotomy 
          Neuropraxia 





















     Primary amputation 
          Minor 
          Major 
 
     Secondary amputation 
          Minor 





     Improvement 
     Unchanged 



































6-Month outcomes  
Thirty patients attended their 6 month follow-up appointments. No further mortalities or 
systemic complications were noted in this group. Seven patients (11.9%) presented with 
procedural complications in the form of bypass graft occlusion (leading to dense 
hemiplegia in one patient and above-elbow amputation in another), re-occlusion of native 
vessels post-embolectomy and improving peripheral nerve neuropraxia (thought to have 
been fasciotomy-related).   
 
Surveillance by clinical examination, hand-held doppler pressures and/or duplex 
arteriogram, revealed deterioration of pulse status in 5 patients, all of which presented 
with bypass graft occlusion.  
 
Twenty-three patients were assessed as having a fully functional ipsilateral upper limb 
(76.7%). Four patients presented with contractures, 1 with motor weakness (affecting 
activities of daily living) and two with claudication symptoms. 
 
Table 26: Summary of 6-month outcome  
Outcome n % 
 
 






Mortalities 0  
   
Morbidities   
     Systemic complications 0  
   
     Procedural complications    
          Bypass graft occlusion 
          Neuropraxia (improving) 















     Secondary amputation 




Pulse status (since 30-day follow-up) 
     Unchanged 




     Normal  
     Contracture 
     Claudication symptoms 































   
 
 
Long term outcome 
Only 17 patients attended follow-up appointments after the 6 months post-operative 
period. One patient developed bypass graft occlusion before demising from lung 
carcinoma 2 months later. No other systemic or procedural complications were noted in 
this patient group.  
 
Three patients showed signs of pulse status deterioration from the previous 6-month 
follow-up visit. Thirteen patients reported normal function, 2 patients presented with 
contractures, 1 patient with motor weakness and 1 patient presenting with claudication 



















Mortalities 1  
   
Morbidities   
     Systemic complications 0  
   
     Procedural complications  








Amputation rate 0  
      
Pulse status (since 6-month follow-up) 
     Unchanged 




     Normal  
     Contracture 
     Claudication symptoms 



























When presenting surgical outcome of patients with upper limb ischaemia as a whole, a 
valuable overall picture of a distinctly heterogeneous disease process, can be obtained. 
However, comparing different subgroups in an attempt to identify significant 
discrepancies in outcome, may facilitate correlation with the international literature on 
these topics. Therefore, relevant subgroup analyses will be discussed next, with specific 
reference to surgical outcome. 
    
 
 
TED vs UEAOD 
It is indeed striking that all 5 of the 30-day mortalities, were observed in the subgroup of 
patients presenting with embolic AULI (see Table 25). The concept that mortality 
following embolectomy is a consequence of the patient’s comorbidity rather than the 
embolus itself, is well supported.[1,52] In our series, the mortalities were attributable to 
acute coronary syndrome (n=2), acute renal failure (n=2) and acute respiratory failure 
(n=1). The only death observed in the CULI group, was documented 2 years after initial 
surgery for UEAOD, when the patient demised from end-stage lung carcinoma.  
 
Table 28: Comparison of TED- and UEAOD- subgroups 
Subgroup      n       Number of  
      procedures 
       Mean 
        age 
  30-Day 









     47 
 





UEAOD 12      16               57              0%  8.3% 
      
 
These findings are in keeping with recent international literature on the subject, where the 
30-day all-cause mortality rate for patients undergoing upper extremity embolectomy, is 
estimated to be between 9 – 19%.[1,138,142,143]  Deguara et al[1] reported a 30-day mortality 
rate of 18.2% in this subgroup of patients and attributed all deaths to cardiopulmonary 
incidents.  
 
Four patients in the TED group underwent amputations (2 above-elbow and 2 digital 
amputations) after revascularization was attempted, compared to one above-elbow 
amputation in the UEAOD group.   
 
Units implementing a more aggressive approach to the management of relatively minor 
symptoms, may reflect better surgical outcomes, especially superior limb salvage rates. 
Therefore, when comparing surgical outcome of the UEAOD subgroup to that of 
international Vascular Units, one has to interpret the results in terms of the indication for 
surgery. In the current series, 48% of patients with UEAOD, presented with some form of 
tissue necrosis as opposed to series from Hughes[9] (15%)  and Roddy[10] (13%).  
 
HIV 
Of the 64 patients included in this review, 7 were confirmed to be HIV positive by HIV 
Ag/Ab Combo (ELISA) testing. However, only 30 patients had documented proof (folder 
laboratory results sheet or NHLS Disa electronic results system) of a recent HIV test being 
performed. Only 3 of the 7 patients had documentation of a recent CD4 count or viral 
load. One patient developed superficial surgical site infection and another demised after 
prosthetic bypass graft sepsis was complicated by an acute bleed. Due to a low rate of HIV 
testing and the small number of patients involved, it is not possible to reach firm 
conclusions regarding clinical outcome in this subgroup of patients.  
 
Patients managed exclusively by endovascular means 
Six patients, of which one presented with AULI from a proximal embolizing source, were 
managed by endovascular means alone. All lesions that were addressed, were located in 
the subclavian artery. Five lesions were managed by primary stent placement, with one 
lesion stented after failed percutaneous balloon angioplasty. One patient sustained a 
procedure related complication in the form of an ipsilateral cerebro-vascular incident. No 
other procedural or systemic complications were noted in this group of patients. All 
 
patients attended follow-up appointments up to 6 months, but only 2 were seen after this 
period. An improvement in pulse status / perfusion (as evaluated by clinical palpation, 
hand-held doppler pressures and/or duplex arteriogram) were noted in all patients and 


















DISCUSSION AND FUTURE RESEARCH PERSPECTIVES 
Vascular surgeons are infrequently confronted with the condition of upper limb ischaemia. 
Compared to other more common vascular pathologies, clinicians are less familiar with 
the pattern and distribution of disease, variable aetiologies, diagnostic appraisal and 
treatment modalities related to this condition. This has generated an innate curiosity 
regarding several facets of ULI, with particular emphases on identifying key areas fit for 
further, more focused research.   
 
On review of the literature, it was clear that even though relatively few patients present 
with this condition, the potential aetiological factors implicated were variable and 
extensive. Therefore, in the interest of developing a broad perspective, the decision was 
made to perform a comprehensive, general overview on the topic, rather than to limit 
oneself to a specific research question.  
 
On evaluation and analysis of the data, certain inherent limitations of the above research 
method, became clear. Unfortunately, by attempting to discuss distinctly different aetio-
pathological processes in unison, important individual characteristics may be obscured. 
Also, with no specific research question asked or stated, the researchers could only 
generate multiple, tentative assumptions to base further research on. With this in mind, a 
few relevant findings will now be discussed.  
   
The true incidence of ULI in the South African context, still remains speculative. A major 
limiting factor is the paucity of data on the non-operative management of AULI. Units 
 
where an initial conservative approach is often utilized should be encouraged to collect 
data regarding the incidence and outcomes. A collaborative effort among units may 
compensate for low numbers and in the process provide adequate data to estimate the true 
extent of the problem. With the high prevalence of pulmonary tuberculosis, HIV / AIDS 
and cigarette smoking (83% in the UEAOD subgroup – Table 16) in the study population, 
it is indeed conceivable that our incidence of ULI may be higher than expected. In the 
absence of a national registry, a multi-centre trial specifically designed to evaluate these 
questions, should be performed.  
 
Another interesting phenomenon is the young age at which patients presented with 
symptomatic disease (Table 12), when compared to international literature. This holds 
especially true for the TED subgroup of patients (mean age 55 years), usually known for 
their advanced age at presentation (72.4 years reported by Deguara et al). Possible 
explanations include the assumed impact that a relatively low life expectancy may have on 
these figures (57.7 years for males and 61.4 years for females) as well as the suspicion of a 
different risk factor profile (TB, HIV and cigarette smoking) compared to other research 
populations.  
 
On review of the referral patterns (Table 14), it is noteworthy that approximately half of 
AULI referrals were received from surrounding Secondary Level Hospitals, as opposed to 
the 19.7% collectively referred from Community Health Centres and Primary Level 
Hospitals. It has incontrovertibly been shown that outcome in patients suffering from ALI 
is superior if managed in a Vascular Unit with 24 hour consultant cover.[164]  Therefore, it 
is imperative that patients are directly referred from the healthcare facility of first contact, 
 
to the nearest Vascular Unit without unnecessary delay. Although multiple other factors 
might have influence this pattern, it will be interesting to evaluate the number of “double 
referrals” within this subgroup of patients in need of urgent revascularization.  
 
Approximately 27% of patients referred were not receiving appropriate pharmacological 
therapies aimed at addressing pre-existing, modifiable risk factors for atherosclerosis. This 
is a worrying statistic bordering on a Public Health catastrophe, as these patients are at an 
increased risk of sustaining adverse cardiovascular events and would benefit from 
evidence-based best medical therapy. Further inquiry should be made through focused 
research, in order to ascertain and further define the system failure at hand.   
 
Poor adherence to follow-up has hampered reliable interpretation of conventional clinical 
outcome. Although variable factors contribute to this phenomenon, the implementation of 
a computerized ULI database with pre-set, automated follow-up reminders may assist 
clinicians and administrative staff in contacting patients due for follow-up visits. 
Compliance to follow-up appointments, as the primary outcome measure, can be evaluated 













Although few firm conclusions could be drawn, this review has expanded our overall 
perspective of ULI, specific to the population we serve. It is anticipated that the 
publication of our institutional data will create a clinical awareness and facilitate future 
research projects in this field. A collaborative research effort between South African 
vascular units will facilitate a comparison of different institutional experiences and enable 
pooled data analysis, perhaps further defining the pattern of upper limb vascular disease 
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APPENDIX 3: DATA COLLECTION SHEET 
 
 
Upper limb ischaemia: Data – collection sheet 
 
Groote Schuur Hospital – Vascular Unit 






Name:      Hospital number: 
Age:          Gender: 
Ethnic group:    
 
Contact details 





Telephone number:          (H)        (W)    




  Acute limb ischaemia  
 Rutherford grading     I    IIa    IIb    III  
 Compartment syndrome    Y     N 
  Chronic limb ischaemia 
    Digital ulceration   
     Active ulceration     Healed ulceration / digital infarcts 
   Digits involved:    
   Raynauds symptoms 
   Claudication symptoms 
   Neuro – vascular symptoms (specify) 
   Risk factors for atherosclerosis 
    Hypertension    Hypercholesterolaemia     DM - Type 
    Cigarette smoking 
  Specify packyears:   
    Other substances 
    Cannabis     TIK  
   Cardiac disease 
    IHD       AF     Valvular heart disease 
   Other systemic disease 
 Specify:  
 
 
  Relevant medical therapy (indicate class of drug) 
 Pre-event:   Anti-HPT       Oral hypoglycaemics 
     Insulin      Chol-lowering agent 
     Anti-platelet agent     Anti-coagulation  
     Anti-TB      ARV’s 
 Post-event:   Anti-HPT       Oral hypoglycaemics 
     Insulin      Chol-lowering agent 
     Anti-platelet agent     Anti-coagulation  
     Anti-TB      ARV’s 
 
Pathology 
   Embolic 
    Cardiac source    
Specify: 
    Extra – cardiac source   
Specify: 
 Site of occlusion: 
   Thrombotic 
    Atherosclerosis associated 
    Thrombophylia 
  Specify: 
    Other 
  Specify:  
 Site of occlusion: 
 
 
Abnormal special investigations 
  Upper limb dopplers 
  Upper limb duplex arteriogram 
  Digital doppler with caloric stimulation 
  Angiogram 
    Arch      Select 
   MD – CTA 
   MRA 
   CXR / C – spine XR 
   Echo / ERNA 
   Laboratory investigations 
Hb     WCC    Platelet count   
  
INR        PTT       Fibrinogen 
ESR     CRP    Homocysteine 
HIV     (CD4=    )  RPR       Lupus a/c 
 AT III        Prot C+S   CardiolipinAb  
 Vit B6     Vit B12    RCF  
 ENA     ANF    RF 
 Complement    Chol    LDL  






Date of procedure:  
Length of procedure: 
  Started during day time hours     Started after hours 
 
   Open surgical 
    Embolectomy  
    Bypass graft 
     Aortic arch recon     SCA - Axillary    Axillary - Brachial 
     Brachial - Brachial    Brachial - Distal   
   Fasciotomy 
    Amputation 
    Above elbow    Below elbow   Hand - Specify: 
   Endovascular          
   On – table angiogram 
    PTA      Stent 
     SCA       Axillary      Brachial 
    Thrombolysis 





Secondary Procedure    
Date of procedure:    
Length of procedure: 
  Started during day time hours     Started after hours 
 
   Open surgical 
    Embolectomy  
    Bypass graft 
     Aortic arch recon     SCA - Axillary    Axillary - Brachial 
     Brachial - Brachial     Brachial - Distal   
   Fasciotomy 
   Amputation 
    Above elbow    Below elbow     Hand - Specify: 
   Endovascular          
   On – table angiogram 
    PTA      Stent 
     SCA       Axillary      Brachial 
    Thrombolysis 
    Alone     In combination with surgery 
 




Follow – up (30 days)   
   Died         Alive 
 Specify reason for death: 
    Systemic complications 
 Specify: 
 
    Procedure related complications 
 Wound complications 
    Wound sepsis  
    Haematoma 
 Graft complications 
     Graft occlusion 
     Graft sepsis 
 Nerve injuries 
 
   Amputation 
   Upper limb     Arm     Hand     Finger 
 
   Pulse status / Doppler pressures 
    Improved      Same      Deteriorated 
 
   Duplex arteriogram 
    Improved      Same      Deteriorated 
 
Follow – up (30 days to 6 months) 
Duration post – procedure:    
   Died         Alive 
 Specify reason for death: 
 
   Graft complications 
     Graft occlusion 
     Graft sepsis 
 
   Pulse status / Doppler pressures 
    Improved      Same      Deteriorated 
 
   Duplex arteriogram 
    Improved      Same      Deteriorated 
 
   Function 
    Normal      Contracture     Claudication 
 





Follow – up (6 months to longterm)    
Duration post – procedure:    
   Died         Alive 
 Specify reason for death: 
 
   Graft complications 
     Graft occlusion 
     Graft sepsis 
 
   Pulse status / Doppler pressures 
    Improved      Same      Deteriorated 
 
   Duplex arteriogram 
    Improved      Same      Deteriorated 
 
   Function 
    Normal      Contracture     Claudication 
 
   Other complications 
 Specify: 
 
 
